US20030083319A1 - 1,3-Dihydroxy-20,20-dialkyl-vitamin D3 analogs - Google Patents
1,3-Dihydroxy-20,20-dialkyl-vitamin D3 analogs Download PDFInfo
- Publication number
- US20030083319A1 US20030083319A1 US10/206,430 US20643002A US2003083319A1 US 20030083319 A1 US20030083319 A1 US 20030083319A1 US 20643002 A US20643002 A US 20643002A US 2003083319 A1 US2003083319 A1 US 2003083319A1
- Authority
- US
- United States
- Prior art keywords
- compound
- alkyl
- independently
- cycloalkyl
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 claims abstract description 25
- 208000001132 Osteoporosis Diseases 0.000 claims abstract description 17
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 claims abstract description 13
- 150000001875 compounds Chemical class 0.000 claims description 115
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 54
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 52
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 44
- 239000011647 vitamin D3 Substances 0.000 claims description 39
- 125000003709 fluoroalkyl group Chemical group 0.000 claims description 30
- 229940021056 vitamin d3 Drugs 0.000 claims description 30
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 28
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 26
- 229910052739 hydrogen Inorganic materials 0.000 claims description 19
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 19
- 239000001257 hydrogen Substances 0.000 claims description 17
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 16
- 239000000651 prodrug Substances 0.000 claims description 15
- 229940002612 prodrug Drugs 0.000 claims description 15
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 14
- 125000006763 (C3-C9) cycloalkyl group Chemical group 0.000 claims description 11
- 125000006002 1,1-difluoroethyl group Chemical group 0.000 claims description 9
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 abstract description 58
- 238000011282 treatment Methods 0.000 abstract description 22
- 208000023275 Autoimmune disease Diseases 0.000 abstract description 5
- 208000011571 secondary malignant neoplasm Diseases 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 216
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 107
- 239000000243 solution Substances 0.000 description 79
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 78
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 59
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 48
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 47
- 239000011541 reaction mixture Substances 0.000 description 44
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 43
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 35
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 35
- 239000000741 silica gel Substances 0.000 description 33
- 229910002027 silica gel Inorganic materials 0.000 description 33
- 238000003818 flash chromatography Methods 0.000 description 31
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- 238000000746 purification Methods 0.000 description 26
- 238000005160 1H NMR spectroscopy Methods 0.000 description 24
- 239000012267 brine Substances 0.000 description 24
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 24
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 22
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 22
- 229910052938 sodium sulfate Inorganic materials 0.000 description 22
- 239000011575 calcium Substances 0.000 description 21
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 21
- 239000000284 extract Substances 0.000 description 20
- 210000000988 bone and bone Anatomy 0.000 description 19
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 19
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 18
- 229910052791 calcium Inorganic materials 0.000 description 18
- 239000012074 organic phase Substances 0.000 description 18
- 235000011152 sodium sulphate Nutrition 0.000 description 18
- 239000007787 solid Substances 0.000 description 18
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 18
- 239000008346 aqueous phase Substances 0.000 description 17
- 239000000543 intermediate Substances 0.000 description 16
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 15
- 239000011736 potassium bicarbonate Substances 0.000 description 15
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 15
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 15
- 239000012266 salt solution Substances 0.000 description 15
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 15
- 0 *C1/C(=C\C=C2/CCC[C@]3(C)C([C@@]([1*])([2*])CCBCC([3*])([4*])O)*CC[C@@]23[H])C[C@@H](O)C[C@@H]1O Chemical compound *C1/C(=C\C=C2/CCC[C@]3(C)C([C@@]([1*])([2*])CCBCC([3*])([4*])O)*CC[C@@]23[H])C[C@@H](O)C[C@@H]1O 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 239000000706 filtrate Substances 0.000 description 14
- 235000015497 potassium bicarbonate Nutrition 0.000 description 13
- 238000003786 synthesis reaction Methods 0.000 description 13
- GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 description 12
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 12
- 208000037147 Hypercalcaemia Diseases 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 12
- 239000011612 calcitriol Substances 0.000 description 12
- 229960005084 calcitriol Drugs 0.000 description 12
- 235000020964 calcitriol Nutrition 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- -1 hydrocarbon radical Chemical class 0.000 description 12
- 230000000148 hypercalcaemia Effects 0.000 description 12
- 108090000445 Parathyroid hormone Proteins 0.000 description 11
- TUESBEDBOMGUOZ-UHFFFAOYSA-N cycloocta-1,5-diene 4-diphenylphosphanylbutyl(diphenyl)phosphane rhodium Chemical compound [Rh].C1=CCCC=CCC1.C1(=CC=CC=C1)P(CCCCP(C1=CC=CC=C1)C1=CC=CC=C1)C1=CC=CC=C1 TUESBEDBOMGUOZ-UHFFFAOYSA-N 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 208000030915 hypercalcemia disease Diseases 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 11
- 239000003981 vehicle Substances 0.000 description 11
- 208000026310 Breast neoplasm Diseases 0.000 description 10
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
- TZIHFWKZFHZASV-UHFFFAOYSA-N anhydrous methyl formate Natural products COC=O TZIHFWKZFHZASV-UHFFFAOYSA-N 0.000 description 10
- 239000002775 capsule Substances 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- GMRQFYUYWCNGIN-UHFFFAOYSA-N 1,25-Dihydroxy-vitamin D3' Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CC(O)C1=C GMRQFYUYWCNGIN-UHFFFAOYSA-N 0.000 description 8
- 206010006187 Breast cancer Diseases 0.000 description 8
- 206010020590 Hypercalciuria Diseases 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 7
- YFPJFKYCVYXDJK-UHFFFAOYSA-N Diphenylphosphine oxide Chemical compound C=1C=CC=CC=1[P+](=O)C1=CC=CC=C1 YFPJFKYCVYXDJK-UHFFFAOYSA-N 0.000 description 7
- 206010029155 Nephropathy toxic Diseases 0.000 description 7
- 239000006260 foam Substances 0.000 description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
- RCBVKBFIWMOMHF-UHFFFAOYSA-L hydroxy-(hydroxy(dioxo)chromio)oxy-dioxochromium;pyridine Chemical compound C1=CC=NC=C1.C1=CC=NC=C1.O[Cr](=O)(=O)O[Cr](O)(=O)=O RCBVKBFIWMOMHF-UHFFFAOYSA-L 0.000 description 7
- 230000007694 nephrotoxicity Effects 0.000 description 7
- 231100000417 nephrotoxicity Toxicity 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 6
- 102000003982 Parathyroid hormone Human genes 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 229910052786 argon Inorganic materials 0.000 description 6
- 239000012300 argon atmosphere Substances 0.000 description 6
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 239000003480 eluent Substances 0.000 description 6
- 239000008273 gelatin Substances 0.000 description 6
- 229920000159 gelatin Polymers 0.000 description 6
- 235000019322 gelatine Nutrition 0.000 description 6
- 235000011852 gelatine desserts Nutrition 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000009806 oophorectomy Methods 0.000 description 6
- 239000000199 parathyroid hormone Substances 0.000 description 6
- 229960001319 parathyroid hormone Drugs 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 102100036893 Parathyroid hormone Human genes 0.000 description 5
- 208000001647 Renal Insufficiency Diseases 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 239000003246 corticosteroid Substances 0.000 description 5
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 201000006370 kidney failure Diseases 0.000 description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 5
- 235000019341 magnesium sulphate Nutrition 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 4
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 208000029725 Metabolic bone disease Diseases 0.000 description 4
- YKFRUJSEPGHZFJ-UHFFFAOYSA-N N-trimethylsilylimidazole Chemical compound C[Si](C)(C)N1C=CN=C1 YKFRUJSEPGHZFJ-UHFFFAOYSA-N 0.000 description 4
- 239000007832 Na2SO4 Substances 0.000 description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 4
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 229910000077 silane Inorganic materials 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 235000010356 sorbitol Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010065687 Bone loss Diseases 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 238000009007 Diagnostic Kit Methods 0.000 description 3
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 3
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 3
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010049088 Osteopenia Diseases 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 229940109239 creatinine Drugs 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- FNIATMYXUPOJRW-UHFFFAOYSA-N cyclohexylidene Chemical group [C]1CCCCC1 FNIATMYXUPOJRW-UHFFFAOYSA-N 0.000 description 3
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000003463 hyperproliferative effect Effects 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 210000002997 osteoclast Anatomy 0.000 description 3
- 230000001009 osteoporotic effect Effects 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 229930195734 saturated hydrocarbon Natural products 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- 102000009310 vitamin D receptors Human genes 0.000 description 3
- 108050000156 vitamin D receptors Proteins 0.000 description 3
- 150000003704 vitamin D3 derivatives Chemical class 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N 1-propanol Substances CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- TUHIBIVYQLRGME-UHFFFAOYSA-N 2-cyclopropylacetaldehyde Chemical compound O=CCC1CC1 TUHIBIVYQLRGME-UHFFFAOYSA-N 0.000 description 2
- LUNMJRJMSXZSLC-UHFFFAOYSA-N 2-cyclopropylethanol Chemical compound OCCC1CC1 LUNMJRJMSXZSLC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000006386 Bone Resorption Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000055006 Calcitonin Human genes 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 201000002980 Hyperparathyroidism Diseases 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 206010029148 Nephrolithiasis Diseases 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 208000015390 Sebaceous gland disease Diseases 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- URZTZMPHTORXSN-ANOFQPTASA-N [H][C@@]12CC[C@H](C3(C/C=C\C(O)(C(F)(F)F)C(F)(F)F)CC3)[C@@]1(C)CCC/C2=C\C=C1\C[C@@H](O)C[C@H](O)C1=C Chemical compound [H][C@@]12CC[C@H](C3(C/C=C\C(O)(C(F)(F)F)C(F)(F)F)CC3)[C@@]1(C)CCC/C2=C\C=C1\C[C@@H](O)C[C@H](O)C1=C URZTZMPHTORXSN-ANOFQPTASA-N 0.000 description 2
- MRIJKSLCYAOCQS-TWJXCYOESA-N [H][C@@]12CC[C@H](C3(CC#CC(O)(C(F)(F)F)C(F)(F)F)CC3)[C@@]1(C)CCC/C2=C\C=C1C[C@@H](O)C[C@H](O)C1 Chemical compound [H][C@@]12CC[C@H](C3(CC#CC(O)(C(F)(F)F)C(F)(F)F)CC3)[C@@]1(C)CCC/C2=C\C=C1C[C@@H](O)C[C@H](O)C1 MRIJKSLCYAOCQS-TWJXCYOESA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001195 anabolic effect Effects 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000037182 bone density Effects 0.000 description 2
- 230000010072 bone remodeling Effects 0.000 description 2
- 230000024279 bone resorption Effects 0.000 description 2
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 229960004015 calcitonin Drugs 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 208000021863 corticosteroid-induced osteoporosis Diseases 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- 102000015694 estrogen receptors Human genes 0.000 description 2
- 108010038795 estrogen receptors Proteins 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 2
- 230000000121 hypercalcemic effect Effects 0.000 description 2
- 230000000642 iatrogenic effect Effects 0.000 description 2
- 201000000916 idiopathic juvenile osteoporosis Diseases 0.000 description 2
- VLQPTWRGZFDXMO-UHFFFAOYSA-N inden-4-one Chemical class O=C1C=CC=C2C=CC=C12 VLQPTWRGZFDXMO-UHFFFAOYSA-N 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000007923 nasal drop Substances 0.000 description 2
- 229940100662 nasal drops Drugs 0.000 description 2
- 238000013059 nephrectomy Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000003334 potential effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- FKHIFSZMMVMEQY-UHFFFAOYSA-N talc Chemical compound [Mg+2].[O-][Si]([O-])=O FKHIFSZMMVMEQY-UHFFFAOYSA-N 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 125000004665 trialkylsilyl group Chemical group 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- HTYVNKCNBDAITQ-NNJDTNATSA-N (2s,8as)-1-(2-hydroxy-2-methylbut-3-enyl)-2,5,5,8a-tetramethyl-3,4,4a,6,7,8-hexahydro-1h-naphthalen-2-ol Chemical compound CC1(C)CCC[C@]2(C)C(CC(O)(C)C=C)[C@@](C)(O)CCC21 HTYVNKCNBDAITQ-NNJDTNATSA-N 0.000 description 1
- NIOUPZZEDGIWIT-UHFFFAOYSA-N 1-[[(z)-diazomethyl]-ethoxyphosphoryl]oxyethane Chemical compound CCOP(=O)(OCC)C=[N+]=[N-] NIOUPZZEDGIWIT-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010054196 Affect lability Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- LXZBQVINMZLYIB-OCLPEPGFSA-N C=C.[H][C@@]12CC[C@H](C3(CC#CC(C)(C)O)CC3)[C@@]1(C)CCC/C2=C\C=C1C[C@@H](O)C[C@H](O)C1 Chemical compound C=C.[H][C@@]12CC[C@H](C3(CC#CC(C)(C)O)CC3)[C@@]1(C)CCC/C2=C\C=C1C[C@@H](O)C[C@H](O)C1 LXZBQVINMZLYIB-OCLPEPGFSA-N 0.000 description 1
- RTSXDPSRGHMWCY-RYJSOWSUSA-N C=C.[H][C@@]12CC[C@H](C3(CC#CC(O)(C(F)(F)F)C(F)(F)F)CC3)[C@@]1(C)CCC/C2=C\C=C1C[C@@H](O)C[C@H](O)C1 Chemical compound C=C.[H][C@@]12CC[C@H](C3(CC#CC(O)(C(F)(F)F)C(F)(F)F)CC3)[C@@]1(C)CCC/C2=C\C=C1C[C@@H](O)C[C@H](O)C1 RTSXDPSRGHMWCY-RYJSOWSUSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000013725 Chronic Kidney Disease-Mineral and Bone disease Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020707 Hyperparathyroidism primary Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 208000030136 Marchiafava-Bignami Disease Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010031240 Osteodystrophy Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 201000000981 Primary Hyperparathyroidism Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 206010039984 Senile osteoporosis Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- PYCUNKUPRKJNDP-ROPQFSKKSA-N [H][C@@]12CC[C@H](C3(C/C=C\C(O)(C(F)(F)F)C(F)(F)F)CC3)[C@@]1(C)CCC/C2=C\C=C1C[C@@H](O)C[C@H](O)C1 Chemical compound [H][C@@]12CC[C@H](C3(C/C=C\C(O)(C(F)(F)F)C(F)(F)F)CC3)[C@@]1(C)CCC/C2=C\C=C1C[C@@H](O)C[C@H](O)C1 PYCUNKUPRKJNDP-ROPQFSKKSA-N 0.000 description 1
- AUSJNZFPQGYCBA-YJCLHHJZSA-N [H][C@@]12CC[C@H](C3(C/C=C\C(O[Si](C)(C)C)(C(F)(F)F)C(F)(F)F)CC3)[C@@]1(C)CCCC2=O Chemical compound [H][C@@]12CC[C@H](C3(C/C=C\C(O[Si](C)(C)C)(C(F)(F)F)C(F)(F)F)CC3)[C@@]1(C)CCCC2=O AUSJNZFPQGYCBA-YJCLHHJZSA-N 0.000 description 1
- ORXVHGFRBZTJJO-LYVDFEQGSA-N [H][C@@]12CC[C@H](C3(CC#CC(C)(C)O)CC3)[C@@]1(C)CCC/C2=C\C=C1C[C@@H](O)C[C@H](O)C1 Chemical compound [H][C@@]12CC[C@H](C3(CC#CC(C)(C)O)CC3)[C@@]1(C)CCC/C2=C\C=C1C[C@@H](O)C[C@H](O)C1 ORXVHGFRBZTJJO-LYVDFEQGSA-N 0.000 description 1
- FJACXWLAMQZBEM-CUWPLCDZSA-N [H][C@@]12CC[C@H](C3(CC#CC(C)(C)O[Si](C)(C)C)CC3)[C@@]1(C)CCCC2=O Chemical compound [H][C@@]12CC[C@H](C3(CC#CC(C)(C)O[Si](C)(C)C)CC3)[C@@]1(C)CCCC2=O FJACXWLAMQZBEM-CUWPLCDZSA-N 0.000 description 1
- FPNVAHHNMNDCQA-QEJZJMRPSA-N [H][C@@]12CC[C@H](C3(CC#CC(O)(C(F)(F)F)C(F)(F)F)CC3)[C@@]1(C)CCCC2=O Chemical compound [H][C@@]12CC[C@H](C3(CC#CC(O)(C(F)(F)F)C(F)(F)F)CC3)[C@@]1(C)CCCC2=O FPNVAHHNMNDCQA-QEJZJMRPSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 235000018660 ammonium molybdate Nutrition 0.000 description 1
- 239000011609 ammonium molybdate Substances 0.000 description 1
- APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 description 1
- 229940010552 ammonium molybdate Drugs 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 229940124325 anabolic agent Drugs 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 1
- 230000000123 anti-resoprtive effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 230000037118 bone strength Effects 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 239000003026 cod liver oil Substances 0.000 description 1
- 235000012716 cod liver oil Nutrition 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- HQWPLXHWEZZGKY-UHFFFAOYSA-N diethylzinc Chemical compound CC[Zn]CC HQWPLXHWEZZGKY-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- NZZFYRREKKOMAT-UHFFFAOYSA-N diiodomethane Chemical compound ICI NZZFYRREKKOMAT-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- JGHYBJVUQGTEEB-UHFFFAOYSA-M dimethylalumanylium;chloride Chemical compound C[Al](C)Cl JGHYBJVUQGTEEB-UHFFFAOYSA-M 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical class CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 208000020089 femoral neck fracture Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 150000004673 fluoride salts Chemical class 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 231100000451 gonadotoxic Toxicity 0.000 description 1
- 230000003605 gonadotoxic effect Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000007887 hard shell capsule Substances 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- VBZWSGALLODQNC-UHFFFAOYSA-N hexafluoroacetone Chemical compound FC(F)(F)C(=O)C(F)(F)F VBZWSGALLODQNC-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 208000031424 hyperprolactinemia Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 229910052745 lead Inorganic materials 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- ARNWQMJQALNBBV-UHFFFAOYSA-N lithium carbide Chemical compound [Li+].[Li+].[C-]#[C-] ARNWQMJQALNBBV-UHFFFAOYSA-N 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 150000002790 naphthalenes Chemical class 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- ASUOLLHGALPRFK-UHFFFAOYSA-N phenylphosphonoylbenzene Chemical class C=1C=CC=CC=1P(=O)C1=CC=CC=C1 ASUOLLHGALPRFK-UHFFFAOYSA-N 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 210000002254 renal artery Anatomy 0.000 description 1
- 201000006409 renal osteodystrophy Diseases 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000006884 silylation reaction Methods 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 206010041569 spinal fracture Diseases 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
Definitions
- This invention relates to 1,3-dihydroxy-20,20-dialkyl-vitamin D 3 analogs, compositions comprising the analogs and methods of treatment of osteoporosis, secondary hyperparathyroidism, cancer and autoimmune diseases using such analogs.
- Osteoporosis is the most common form of metabolic bone disease and may be considered the symptomatic, fracture stage of bone loss (osteopenia). Although osteoporosis may occur secondary to a number of underlying diseases, 90% of all cases appear to be idiopathic. Postmenopausal women are at risk for idiopathic osteoporosis (postmenopausal or Type I osteoporosis); another particularly high risk group for idiopathic osteoporosis is the elderly of either sex (senile or Type II osteoporosis).
- Osteoporosis has also been related to corticosteroid use, immobilization or extended bed rest, alcoholism, diabetes, gonadotoxic chemotherapy, hyperprolactinemia, anorexia nervosa, primary and secondary amenorrhea, transplant immunosuppression, and oophorectomy.
- Postmenopausal osteoporosis is characterized by fractures of the spine, while femoral neck fractures are the dominant features of senile osteoporosis.
- osteoporotics The mechanism by which bone is lost in osteoporotics is believed to involve an imbalance in the process by which the skeleton renews itself. This process has been termed bone remodeling. It occurs in a series of discrete pockets of activity. These pockets appear spontaneously within the bone matrix on a given bone surface as a site of bone resorption. Osteoclasts (bone dissolving or resorbing cells) are responsible for the resorption of a portion of bone of generally constant dimension. This resorption process is followed by the appearance of osteoblasts (bone forming cells) which then refill with new bone the cavity left by the osteoclasts.
- bone remodeling It occurs in a series of discrete pockets of activity. These pockets appear spontaneously within the bone matrix on a given bone surface as a site of bone resorption. Osteoclasts (bone dissolving or resorbing cells) are responsible for the resorption of a portion of bone of generally constant dimension. This resorption process is followed by the appearance of osteoblasts (bone forming cells)
- osteoblasts and osteoclasts function so that bone formation and bone resorption are in balance.
- an imbalance in the bone remodeling process develops which results in bone being replaced at a slower rate than it is being lost.
- this imbalance occurs to some extent in most individuals as they age, it is much more severe and occurs at a younger age in postmenopausal osteoporotics, following oophorectomy, or in iatrogenic situations such as those resulting from corticosteroid therapy or the immunosuppression practiced in organ transplantation.
- Vitamin D 3 is a critical element in the metabolism of calcium, promoting intestinal absorption of calcium and phosphorus, maintaining adequate serum levels of calcium and phosphorus, and stimulating flux of calcium into and out of bone.
- the D vitamins are hydroxylated in vivo, with the resulting 1:,25-dihydroxy metabolite being the active material.
- Animal studies with 1,25-(OH) 2 vitamin D 3 have suggested bone anabolic activity.
- Aerssens et al., in Calcif Tissue Int, 55:443-450 (1994) reported upon the effect of 1 ⁇ -hydroxy vitamin D 3 on bone strength and composition in growing rats with and without corticosteroid treatment.
- human usage is restricted to antiresorption due to the poor therapeutic ratio (hypercalciuria and hypercalcemia as well as nephrotoxicity).
- This invention provides novel vitamin D 3 derivatives which have more favorable therapeutic doses.
- This invention provides novel vitamin D 3 derivatives for the treatment of hyperproliferative disorders of the skin, malignant tumors such as leukemia, colon and breast cancers, autoimmune diseases such as diabetes and for the treatment of sebaceous gland diseases which have more favorable therapeutic ratios or margins.
- This invention provides novel vitamin D 3 derivatives which have more favorable therapeutic windows.
- X is hydrogen or ⁇ CH 2 ;
- R 1 and R 2 are, independently of each other, a (C 1 -C 4 )alkyl or (C 1 -C 4 )fluoroalkyl, or R 1 and R 12 together with C20 form a (C 3 -C 6 )cycloalkyl or (C 3 -C 6 )cyclofluoroalkyl, or R 1 and R 2 together form ⁇ CH 2 ;
- R 3 and R 4 are, independently of each other, a (C 1 -C 4 )alkyl or (C 1 -C 4 )fluoroalkyl, or R 3 and R 4 together with C25 form a (C 3 -C 9 )cycloalkyl or (C 3 -C 9 )cyclofluoroalkyl;
- A is a single or a double bond
- B is a single, double or triple bond
- a second aspect of this invention relates to a method for treating osteoporosis or secondary hyperparathyroidism via administration of a compound of Formula (I), wherein:
- X is hydrogen or ⁇ CH 2 ;
- R 1 and R 2 are, independently of each other, a (C 1 -C 4 )alkyl or (C 1 -C 4 )fluoroalkyl, or R 1 and R 2 together with C20 form a (C 3 -C 6 )cycloalkyl or (C 3 -C 6 )cyclofluoroalkyl, or R 1 and R 2 together form ⁇ CH 2 ;
- R 3 and R 4 are, independently of each other, a (C 1 -C 4 )alkyl or (C 1 -C 4 )fluoroalkyl, or R 3 and R 4 together with C25 form a (C 3 -C 9 )cycloalkyl or (C 3 -C 9 )cyclofluoroalkyl;
- A is a single or a double bond
- B is a single, double or triple bond
- prodrugs thereof in an amount therapeutically effective to restore bone density to an asymptomatic level, without inducing hypercalciuria, hypercalcemia, or nephrotoxicity.
- a third aspect of this invention relates to a method for treating cancer via administration of a compound of Formula (I), wherein:
- X is hydrogen or ⁇ CH 2 ;
- R 1 and R 2 are, independently of each other, a (C 1 -C 4 )alkyl or (C 1 -C 4 )fluoroalkyl, or R 1 and R 2 together with C20 form a (C 3 -C 6 )cycloalkyl or (C 3 -C 6 )cyclofluoroalkyl, or R 1 and R 2 together form ⁇ CH 2 ;
- R 3 and R 4 are, independently of each other, a (C 1 -C 4 )alkyl or (C 1 -C 4 )fluoroalkyl, or R 3 and R 4 together with C25 form a (C 3 -C 9 )cycloalkyl or (C 3 -C 9 )cyclofluoroalkyl;
- A is a single or a double bond
- B is a single, double or triple bond
- a fourth aspect of this invention relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a vitamin D 3 analog of Formula (I).
- vitamin D 3 analogs of the present invention have the following general structure:
- X is hydrogen or ⁇ CH 2 ;
- R 1 and R 2 are, independently of each other, a (C 1 -C 4 )alkyl or (C 1 -C 4 )fluoroalkyl, or R and R 2 together with C20 form a (C 3 -C 6 )cycloalkyl or (C 3 -C 6 )cyclofluoroalkyl, or R 1 and R 2 together form ⁇ CH 2 ;
- R 3 and R 4 are, independently of each other, a (C 1 -C 4 )alkyl or (C 1 -C 4 )fluoroalkyl, or R 3 and R 4 together with C25 form a (C 3 -C 9 )cycloalkyl or (C 3 -C 9 )cyclofluoroalkyl;
- A is a single or a double bond
- B is a single, double or triple bond
- R 1 and R 2 are (C 1 -C 4 )alkyl or R 1 and R 2 together with C20 form a cyclopropyl group or ⁇ CH 2
- R 3 and R 4 are (C 1 -C 4 )alkyl, trifluoromethyl or R 3 and R 4 together with C25 form (C 3 -C 6 )cycloalkyl and A is a single bond, then B is not a trans double bond;
- X is hydrogen or ⁇ CH 2 ;
- R 1 and R 2 are, independently of each other, a (C 1 -C 4 )alkyl or (C 1 -C 4 )fluoroalkyl, or R 1 and R 2 together with C20 form a (C 3 -C 6 )cycloalkyl or (C 3 -C 6 )cyclofluoroalkyl, or R 1 and R 2 together form ⁇ CH 2 ;
- R 3 and R 4 are, independently of each other, a (C 1 -C 4 )alkyl or (C 1 -C 4 )fluoroalkyl, or R 3 and R 4 together with C25 form a (C 3 -C 9 )cycloalkyl or (C 3 -C 9 )cyclofluoroalkyl;
- A is a single or a double bond
- B is a single, double or triple bond
- prodrugs thereof in an amount therapeutically effective to restore bone density to an asymptomatic level, without inducing hypercalciuria, hypercalcemia, or nephrotoxicity.
- X is hydrogen or ⁇ CH 2 ;
- R 1 and R 2 are, independently of each other, a (C 1 -C 4 )alkyl or (C 1 -C 4 )fluoroalkyl, or R 1 and R 2 together with C20 form a (C 3 -C 6 )cycloalkyl or (C 3 -C 6 )cyclofluoroalkyl, or R 1 and R 2 together form ⁇ CH 2 ;
- R 3 and R 4 are, independently of each other, a (C 1 -C 4 )alkyl or (C 1 -C 4 )fluoroalkyl, or R 3 and R 4 together with C25 form a (C 3 -C 9 )cycloalkyl or (C 3 -C 9 )cyclofluoroalkyl;
- A is a single or a double bond
- B is a single, double or triple bond
- (C 1 -C 4 ) alkyl means a fully-saturated hydrocarbon radical having one to four carbon atoms; a (C 1 -C 4 ) fluoroalkyl is an alkyl radical, as defined above, in which one or more hydrogen atoms attached to the carbon backbone have been substituted with one or more fluorine atoms.
- a (C 3 -C 6 ) cycloalkyl is a cyclic saturated hydrocarbon radical having three to six ring carbon atoms; a (C 3 -C 6 ) cyclofluoroalkyl is a cycloalkyl radical, as defined above, in which one or more hydrogen atoms attached to the carbon backbone have been substituted with one or more fluorine atoms.
- a (C 3 -C 9 ) cycloalkyl is a cyclic saturated hydrocarbon radical having three to nine ring carbon atoms; a (C 3 -C 9 ) cyclofluoroalkyl is a cyclic saturated hydrocarbon radical having three to nine carbon atoms in which one or more hydrogen atoms attached to the carbon backbone have been substituted with one or more fluorine atoms.
- double bond it is meant an unsaturated linkage between two adjacent carbon atoms in which two pairs of electrons are shared equally, and wherein each carbon atom bears two single-bonded substituents in either a cis (Z) or a trans (E) configuration about the double bond.
- Pro-drugs means any compound which releases an active parent drug according to Formula (I) in vivo when such prodrug is administered to a mammalian subject.
- Prodrugs of a compound of Formula (I) are prepared by modifying functional groups present in the compound of Formula (I) in such a way that the modifications may be cleaved in vivo to release the parent compound.
- Prodrugs include compounds of Formula (I) wherein a hydroxy group in compound (I) is bonded to any group that may be cleaved in vivo to regenerate the free hydroxyl group.
- prodrugs include, but are not limited to esters (e.g., acetate, formate, and benzoate derivatives), carbamates (e.g., N,N-dimethylaminocarbonyl) and ethers of hydroxy functional groups in compounds of Formula (I), and the like.
- esters e.g., acetate, formate, and benzoate derivatives
- carbamates e.g., N,N-dimethylaminocarbonyl
- ethers of hydroxy functional groups in compounds of Formula (I) and the like.
- Such compounds are routinely made by one of skill in the art by acylating or etherifying the hydroxy group in the parent molecule.
- a “therapeutically effective amount” means the amount of a compound that, when administered to a mammal for treating or preventing a disease, is sufficient to effect such treatment or prevention for the disease.
- the “therapeutically effective amount” will vary depending on the compound, the disease and its severity and the age, weight, etc., of the mammal to be treated.
- the compounds of the present invention may be generically described as 1 ⁇ ,25-dihydroxy-20,20-dialkyl and 1 ⁇ ,25-dihydroxy-20,20-dialkyl-19-nor analogs of vitamin D 3 .
- a compound of the invention where X is ⁇ CH 2 , R 1 and R 2 together form a cyclopropyl group, A is a single bond and B is a triple bond is named as 1 ⁇ -25-dihydroxy-23-yne-20,21,28-cyclopropyl-cholecalciferol.
- A is a single or a double bond, preferably a single bond
- B is a triple bond.
- A is a double bond
- A is a single or a double bond, preferably a single bond
- R 1 and R 2 together with C20 form a (C 3 -C 6 )cycloalkyl, preferably a cyclopropyl;
- R 3 and R 4 are, independently of each other, a (C 1 -C 4 )alkyl or a (C 1 -C 4 )fluoroalkyl, preferably methyl, ethyl, trifluoromethyl, 1,1-difluoroethyl or 2,2,2-trifluoroethyl, more preferably methyl or trifluoromethyl.
- Analogs of this invention may generally be prepared by reaction and combination of fragments of Vitamin D 3 molecules (see e.g., Shiuey et al., J. Org. Chem, 55:243 (1990); Wovkulich, P. M. et al., Tetrahedron, 40, 2283 (1984); Baggiolini E. B. et al J. Org. Chem., 51, 3098-3108, (1986) and Steinmeyer et al., U.S. Pat. No. 5,585,368.
- the starting materials and reagents used in preparing these compounds are either available from commercial suppliers such as Aldrich Chemical Co., (Milwaukee, Wis.), or Sigma (St. Louis, Mo.) or they can be prepared by methods known to those skilled in the art following procedures set forth in references such as Fieser and Fieser's Reagents for Organic Synthesis , Vol. 1-15 (John Wiley and Sons, 1991); March's Advanced Organic Chemistry , (John Wiley and Sons 4th Edition) and Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989).
- the starting materials and the intermediates of the reaction may be isolated and purified if desired using conventional techniques, including but not limited to filtration, distillation, crystallization, chromatography and the like. Such materials may be characterized using conventional means, including physical constants and spectral data.
- a compound of Formula (I) is prepared by coupling a 4H-inden-4-one derivative of Formula (II) where R 1 , R 2 , R 3 , R 4 , A and B are as described in the Summary of the Invention and R 5 is hydrogen or a hydroxy protecting group (e.g., trialkylsilyl, preferably trimethylsilyl) with a diphenylphosphine oxide derivative of a compound of Formula (III) where X is hydrogen or ⁇ CH 2 , as shown in Scheme I below.
- R 1 , R 2 , R 3 , R 4 , A and B are as described in the Summary of the Invention and R 5 is hydrogen or a hydroxy protecting group (e.g., trialkylsilyl, preferably trimethylsilyl)
- R 5 is hydrogen or a hydroxy protecting group (e.g., trialkylsilyl, preferably trimethylsilyl)
- X is hydrogen or ⁇ CH 2
- the coupling reaction is carried out in the presence of a strong base such as an alkyllithium like n-butyllithium in a mixture of hexane and tetrahydrofuran at ⁇ 78° C. to give a trisilyl derivative of compound of Formula (I).
- a strong base such as an alkyllithium like n-butyllithium in a mixture of hexane and tetrahydrofuran at ⁇ 78° C.
- preparation of a compound of Formula (II) involves preparation of a common intermediate, 1-[(5-hydroxy)-3-alkynyl]-inden-4-ol derivative (VII), which is then converted to a compound of Formula (II) where B is either a double or a triple bond by following method (a) or method (b) respectively.
- Compound (VII) is prepared by condensation of lithium acetylide derived from a 1-(3-alkynyl)-4-tert-butyldimethylsilyloxy-7a-methyl-indene derivative (IV) with a ketone of Formula (V) where R 3 and R 4 are as defined in the Summary of the Invention to give a 1-[(5-hydroxy)-3-alkynyl]-4-tert-butyldimethylsilyloxy-7a-methyl-indene derivative (VI).
- the condensation reaction is carried out in the presence of a strong base such as n-butyllithium in an aprotic organic solvent such as tetrahydrofuran and at low temperatures ranging between ⁇ 50 to ⁇ 100° C. Removal of the silyl group with tetrabutylammonium fluoride in an suitable organic solvent such as tetrahydrofuran gives the 1-[(5-hydroxy)-3-alkynyl]-inden-4-ol derivative (VII).
- a strong base such as n-butyllithium
- an aprotic organic solvent such as tetrahydrofuran
- a compound of Formula (II) where B is a triple bond and R 5 is hydrogen is prepared, as shown in method (a), by oxidation of the hydroxy group at the 4-position in compound (VII) to the keto group with a suitable oxidizing agent such as pyridinium dichromate at room temperature.
- a suitable oxidizing agent such as pyridinium dichromate at room temperature.
- the oxidation reaction is carried out in a chlorinated hydrocarbon solvent such as methylene chloride, chloroform and the like.
- a compound of Formula (II) where W is hydrogen is converted to the corresponding compound of Formula (II) where R is trialkylsilyl, preferably trimethylsilyl, by reacting it with a suitable silylating agent such as 1-trimethylsilylimidazole in a non-alcoholic organic solvent such as tetrahydrofuran, methylene chloride, preferably methylene chloride, and the like.
- a suitable silylating agent such as 1-trimethylsilylimidazole
- a non-alcoholic organic solvent such as tetrahydrofuran, methylene chloride, preferably methylene chloride, and the like.
- a compound of Formula (II) where B is a double bond is prepared, as shown in method (b), by partial reduction of the triple bond in compound (VII) with a suitable reducing agent to give a 3-alkene-4H-inden-4-ol of Formula (VIII).
- the choice of the reducing agent depends on the configuration about the double bond. If the E configuration is desired, then the reduction is carried out with lithium aluminum hydride in the presence of an alkali metal alkoxide, such as sodium methoxide, and in an aprotic organic solvent like ether or more preferably tetrahydrofuran. If the Z configuration is desired, then the reduction is carried out with Lindlar's catalyst.
- a reaction scheme showing the preparation of a compound of Formula (I) where A is a single bond, B is a single bond, R 1 and R 2 form a cyclopropyl ring and X is ⁇ CH 2 is shown below in Scheme III and is described further in Example 10.
- the compounds of this invention are useful for the prevention and treatment of a variety of mammalian conditions manifested by loss of bone mass.
- the compounds of this invention are anabolic agents and are indicated for the prophylaxis and therapeutic treatment of osteoporosis and osteopenia in mammals without inducing hypercalciuria, hypercalcemia, or nephrotoxicity.
- hypercalciuria is excessive calcium in the urine, in humans corresponding to an excretion of greater than about 4 mg/kg/day. This often results in nephrolithiasis (renal calculi).
- “Hypercalcemia” is an excessive concentration of calcium in the serum; in humans (and rats) this corresponds to greater than about 10.5 mg/dl.
- Withinlerable hypercalcemia usually occurring at serum calcium concentrations greater than about 12 mg/dl, is associated with emotional lability, confusion, delirium, psychosis, stupor, and coma.
- the compounds of this invention are expected to be useful in the treatment of Type I (postmenopausal), Type II (senile), and Type III (iatrogenic) osteoporosis, including that associated with immunosuppressive drugs used in organ transplantation, as well in the treatment of osteodystrophy due to renal dialysis and secondary hyperparathyroidism.
- Compounds of this invention are also useful in treating diseases caused by elevated levels of parathyroid hormone.
- compounds of the invention are used in treating secondary hyperparathyroidism associated with renal failure and in particular with reversing or reducing the bone loss associated with renal insufficiency.
- Other aspects include the treatment of renal osteodystrophy associated with late stage secondary hyperparathyroidism.
- Other aspects include the treatment of primary hyperparathyroidism.
- Compounds of Formula (I) are also useful in treating neoplastic diseases such as leukemia, colon cancer, breast cancer and prostate cancer.
- Compounds of Formula (I) are also useful in treating immunosuppressive and autoimmune diseases. Such diseases include, but are not limited to, multiple sclerosis, systemic lupus erythematosus, diabetes, thyroiditis and allograft rejection.
- diseases include, but are not limited to, multiple sclerosis, systemic lupus erythematosus, diabetes, thyroiditis and allograft rejection.
- compounds of Formula (I) are useful to treat diseases via modulation of the activity of the vitamin D 3 receptor (VDR).
- VDR vitamin D 3 receptor
- the utility of these compounds is demonstrated in vivo using murine models for these diseases as is well known in the art. See, e.g., Lemire et al., Autoimmunity, 12:143-148 (1992); Lemire et. al., J. Clin. Invest., 87:1103-1107 (1991), Lemire et al., Endocrinology, 135:2818 (1994), and Le
- the bone anabolic activity of the compounds of the invention was demonstrated in vivo in the ovariectomized rat model as described in detail in Example 10.
- the anti-cell proliferation activity of the compounds of the invention was demonstrated in vitro as described in detail in Examples 11 and 12.
- the parathyroid hormone suppressive activity of the compounds of the invention was demonstrated in vivo as described in detail in Example 13.
- the compound of this invention may be administered in amounts between about 0.0002 and 5 ⁇ g per day, preferably from about 0.001 to about 2 ⁇ g per day, most preferably from about 0.002 to about 1 ⁇ g per day.
- the daily dose of active ingredient may be from about 0.01 to about 250 ⁇ g, preferably from about 0.05 to about 100 ⁇ g, most preferably from about 0.1 to about 50 ⁇ g per day.
- This dosage may be delivered in a conventional pharmaceutical composition by a single administration, by multiple applications, or via controlled release, as needed to achieve the most effective results, preferably once or twice daily by mouth. In certain situations, alternate day dosing may prove adequate to achieve the desired therapeutic response.
- the selection of the exact dose and composition and the most appropriate delivery regimen will be influenced by, inter alia, the pharmacological properties of the formulation, the nature and severity of the condition being treated, and the physical condition and mental acuity of the recipient. In the treatment of corticosteroid induced osteopenia, it is expected that the requisite dose will be greater for higher doses of corticosteroids.
- Representative delivery regimens include oral, parenteral (including subcutaneous, intramuscular and intravenous), rectal, buccal (including sublingual), pulmonary, transdermal, and intranasal, most preferably oral.
- compositions comprising as an active ingredient a compound of the present invention, in admixture with a pharmaceutically acceptable, non-toxic carrier.
- a pharmaceutically acceptable, non-toxic carrier may be prepared for parenteral (subcutaneous, intramuscular or intravenous) administration, particularly in the form of liquid solutions or suspensions; for oral or buccal administration, particularly in the form of tablets or capsules; for pulmonary or intranasal administration, particularly in the form of powders, nasal drops or aerosols; and for rectal or transdermal administration.
- compositions may conveniently be administered in unit dosage form and may be prepared by any of the methods well-known in the pharmaceutical art, for example as described in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., (1985).
- Formulations for parenteral administration may contain as excipients sterile water or saline, alkylene glycols such as propylene glycol, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, hydrogenated naphthalenes and the like.
- Formulations for nasal administration may be solid and may contain excipients, for example, lactose or dextran, or may be aqueous or oily solutions for use in the form of nasal drops or metered spray.
- typical excipients include sugars, calcium stearate, magnesium stearate, pregelatinated starch, and the like.
- Orally administrable compositions may comprise one or more physiologically compatible carriers and/or excipients and may be in solid or liquid form, including, for example, tablets, coated tablets, capsules, lozenges, aqueous or oily suspensions, solutions, emulsions, elixirs, and powders suitable for reconstitution with water or another suitable liquid vehicle before use.
- Tablets and capsules may be prepared with binding agents, for example, syrup, acacia, gelatin, sorbitol, tragacanth, or poly-vinylpyrollidone; fillers, such as lactose, sucrose, corn starch, calcium phosphate, sorbitol, or glycine; lubricants, such as magnesium stearate, talc, polyethylene glycol, or silica; and surfactants, such as sodium lauryl sulfate.
- binding agents for example, syrup, acacia, gelatin, sorbitol, tragacanth, or poly-vinylpyrollidone
- fillers such as lactose, sucrose, corn starch, calcium phosphate, sorbitol, or glycine
- lubricants such as magnesium stearate, talc, polyethylene glycol, or silica
- surfactants such as sodium lauryl sulfate.
- Liquid compositions may contain conventional additives such as suspending agents, for example sorbitol syrup, methyl cellulose, sugar syrup, gelatin, carboxymethylcellulose, or edible fats; emulsifying agents such as lecithin, or acacia; vegetable oils such as almond oil, coconut oil, cod liver oil, or peanut oil; preservatives such as butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT).
- suspending agents for example sorbitol syrup, methyl cellulose, sugar syrup, gelatin, carboxymethylcellulose, or edible fats
- emulsifying agents such as lecithin, or acacia
- vegetable oils such as almond oil, coconut oil, cod liver oil, or peanut oil
- preservatives such as butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT).
- Liquid compositions may be encapsulated in, for example, gelatin to provide a unit dosage form.
- Preferred solid oral dosage forms include tablets, two-piece hard shell capsules and soft elastic gelatin (SEG) capsules.
- SEG capsules are of particular interest because they provide distinct advantages over the other two forms (see Seager, H., “Soft gelatin capsules: a solution to many tableting problems”; Pharmaceutical Technology, 9, (1985).
- SEG capsules Some of the advantages of using SEG capsules are: a) dose-content uniformity is optimized in SEG capsules because the drug is dissolved or dispersed in a liquid that can be dosed into the capsules accurately, b) drugs formulated as SEG capsules show good bioavailability because the drug is dissolved, solubilized or dispersed in an aqueous-miscible or oily liquid and therefore when released in the body produce drug dispersions of high surface area and c) degradation of drugs that are sensitive to oxidation during long-term storage is prevented because the dry shell of soft gelatin provides a barrier against the diffusion of oxygen.
- the dry shell formulation typically comprises of about 40% to 60% concentration of gelatin, about a 20% to 30% concentration of plasticizer (such as glycerin, sorbitol or propylene glycol) and about a 30 to 40% concentration of water. Other materials such as preservatives, dyes, opacifiers and flavours also may be present.
- the liquid fill material comprises a solid drug that has been dissolved, solubilized or dispersed (with suspending agents such as beeswax, hydrogenated castor oil or polyethylene glycol 4000) or a liquid drug in vehicles or combinations of vehicles such as mineral oil, vegetable oils, triglycerides, glycols, polyols and surface-active agents.
- reaction mixture was stirred at 5-7° C. for 4.25 h and then poured into a mixture of hexanes (25 ml) and 0.1 N sulfuric acid (150 ml).
- the product was extracted into hexanes and the extracts were washed with brine, dried over magnesium sulfate and evaporated in vacuo to give 5.34 g of a pale yellow gum.
- Fluorosilicic acid (3.75 ml, 30% aqueous solution prepared as described in Pilcher, A. S. and DeShong, P. J. Org. Chem., 58, 5130 (1993)) was added to a solution of [1R-(1 ⁇ ,3a ⁇ ,4 ⁇ ,7a ⁇ )]-5-[1-[4-[[1,1-dimethylethyl)dimethylsilyl]oxy]octahydro-7a-methyl-1H-inden-1-yl]cyclopropyl]-2-methyl-3-pentyn-2-ol (0.8 g, 2.0 mmol),), [prepared as described in Step 5 above] in acetonitrile (12 ml) at 0° C.
- reaction mixture was allowed to warm to 15° C. After 3.5 h, the reaction mixture was diluted with water (10 ml) and ethyl acetate (10 ml) and then poured into a mixture of ethyl acetate (100 ml) and water (50 ml). The organic layer was separated and washed with brine, saturated sodium bicarbonate, dried over sodium sulfate and evaporated in vacuo to give a gum.
- Fluorosilicic acid (6.0 ml, 30% aqueous solution prepared as described in Pilcher, A. S. and DeShong, P. J. Org. Chem., 58, 5130 (1993)) was added to a solution of [1R-(1 ⁇ ,3a ⁇ ,4 ⁇ ,7a ⁇ )]-5-[1-[4-[[11,1-dimethylethyl)dimethylsilyl]oxy]octahydro-7a-methyl-1H-inden-1-yl]cyclopropyl]-1,1,1-trifluoro-2-(trifluoromethyl)-3-pentyn-2-ol (1.24 g, 2.40 mmol), [prepared as described in Step 1 above] in acetonitrile (18 ml) and the reaction mixture was stirred at room temperature under an argon atmosphere.
- reaction mixture was poured into a mixture of ethyl acetate (100 ml) and saturated sodium bicarbonate (50 ml). The organic layer was separated and washed with brine, dried over sodium sulfate and evaporated in vacuo to give 0.9 g of a partially crystalline solid.
- Tetrabutylammonium fluoride (2.5 ml, 2.5 mmol, 1M solution in tetrahydrofuran) was added to a solution of the trisilyl intermediate (0.145 g, 0.19 mmol) in anhydrous tetrahydrofuran (3.0 ml) and the reaction mixture was stirred at room temperature under an argon atmosphere. After 19 h, the reaction mixture was diluted with water (10 ml), stirred for an additional 10 min. and then poured into a mixture of ethyl acetate (75 ml) and a 1:1 mixture of brine/water (50 ml).
- Tetrabutylammonium fluoride (2.5 ml, 2.5 mmol, 1M solution in tetrahydrofuran) was added to a solution of above trisilyl intermediate (0.15 g, 0.20 mmol) in anhydrous tetrahydrofuran (3.0 ml). The reaction mixture was stirred under argon at room temperature for 40 h, then diluted with water (10 ml) and poured into ethyl acetate (75 ml) and a 1:1 mixture of brine/water (50 ml). The organic phase was collected and the aqueous phase was re-extracted with ethyl acetate.
- Tetrabutylammonium fluoride (3.0 ml, 3.0 mmol, 1.0 M solution in tetrahydrofuran) was added to a solution of the trisilyl intermediate (0.11 g) in tetrahydrofuran ⁇ 3 ml) and the reaction mixture was stirred at room temperature. After 17 h, the reaction mixture was diluted with water (5 ml), stirred for additional 15 min., and then poured into a mixture of ethyl acetate (50 ml) and 50% brine (40 ml). The organic phase was collected and the aqueous phase was re-extracted with ethyl acetate.
- reaction mixture was diluted with ethyl acetate (15 ml), poured into a mixture of ethyl acetate (50 ml) and a 1:1 mixture of 2 N Rochelle salt solution and 2 N potassium bicarbonate solution (50 ml).
- the organic phase was collected and the aqueous phase was re-extracted with ethyl acetate.
- the combined organic extracts were washed with 50% brine, dried over sodium sulfate and evaporated to give 0.58 g of a gum.
- Tetrabutylammonium fluoride (3.0 ml, 3.0 mmol, 1.0 M solution in tetrahydrofuran) was added to a solution of the trisilyl intermediate (0.18 g) in tetrahydrofuran (3 ml) and the reaction mixture was stirred at room temperature. After 42 h, the reaction mixture was diluted with water (5 ml), stirred for an additional 15 min., and then poured into a mixture of ethyl acetate (50 ml) and 50% brine (40 ml). The organic phase was collected and the aqueous phase was re-extracted with ethyl acetate.
- the compounds of the present invention are more effective than 1,25-dihydroxy vitamin D 3 at bone accretion and do not induce hypercalciuria, nephrotoxicity, or hypercalcemia at therapeutically effective doses. This has been demonstrated as follows:
- the bone mineral density of the right femur was determined by using a High Resolution Software Package on a QDR-1000W Bone DensitometerTM (Hologic, Walthan, Mass.). The animals were scanned by placing them on a scanning block in a supine position such that the right leg was perpendicular to the main body and the tibia was perpendicular to the femur.
- MCF-7 cells are human mammary carcinoma cells that are positive for estrogen receptors. The potential activity of vitamin D 3 analogs against breast cancer was assessed from inhibition of proliferation of MCF-7 cells in culture.
- MCF-7 cells were plated at 9000 cells/well in 24-well plates and incubated at 37° C. in 5% CO 2 /95% air in Dulbecco's Modified Eagle Medium containing 10% fetal bovine serum, 700 nM insulin, 2 mM glutamine, 0.1 mM MEM non-essential amino acids and 1 mM sodium pyruvate.
- Stock solutions of vitamin D 3 analogs were prepared at a concentration of 10 mM in absolute ethanol and stored at ⁇ 20° C. under argon.
- the number of MCF-7 were counted by removing the medium in 8 wells, rinsing the cells with 0.5 ml PBS without Ca/Mg and then incubating the cells with 0.3 ml of trypsin-EDTA. After 15 min., the trypsinization was stopped by adding 0.3 ml of medium. 0.2 ml aliquot was transferred from each well into dilu-vials containing 10 ml isoton and the number of cells were counted on Coulter CounterTM (Coulter, Miami, Fla.).
- MCF-7 cells in the remaining wells were refed with either control medium or medium containing varying concentrations of the vitamin D 3 analog. After a further 7 days of culture, the number of MCF-7 cells in each well was assessed by removing the medium, rinsing the cells with 0.5 ml PBS without Ca/Mg and then incubating the cells with 0.5 ml of trypsin-EDTA for 15 min. The trypsinization was stopped by adding 0.5 ml of medium and 0.1 ml aliquot from each well was transferred into dilu-vials containing 10 ml isoton and the number of cells were counted on Coulter CounterTM.
- IC 50 the concentration causing 50% reduction in MCF-7 cell growth in culture
- 1,25-dihydroxy-cholecalciferol as a comparator
- ZR-75 cells are human mammary carcinoma cells that are positive for estrogen receptors. The potential activity of vitamin D 3 analogs against breast cancer was assessed from inhibition of proliferation of ZR-75 cells in culture.
- ZR-75 cells were plated at 12,500 cells/well in 24-well plates and incubated at 37° C. in 5% CO 2 /95% air in RPMI medium containing 10% fetal bovine serum and 2 mM L-glutamine.
- Stock solutions of vitamin D 3 analogs were prepared at a concentration of 10 mM in absolute ethanol and stored at ⁇ 20° C. under argon.
- ZR-75 cells were refed with either control medium or medium containing varying concentrations of the vitamin D 3 analog.
- the number of ZR-75 cells in each well was assessed from the reduction of the dye MTT (3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide), as described by F. Denizot and R. Lang, J. Immunological Methods , Vol. 89:271-277 (1986). MTT was added to each well to a final concentration of 1 mg/ml and the cells were incubated for a period of three hours, after which reduced MTT was extracted using 95% ethanol and the optical density was measured at a wavelength of 570 nm.
- MTT 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide
- the IC 50 value was determined from a graph relating the optical density of 570 nm to the concentration used.
- IC 50 concentration of the vitamin D 3 analog corresponding to half-maximal reduction in 570 nm absorbance
- IC 50 concentration of the vitamin D 3 analog corresponding to half-maximal reduction in 570 nm absorbance
- 1,25-dihydroxy-cholecalciferol as a comparator
- a capsule for oral administration is formulated under nitrogen in amber light from 0.01 to 25.0 mg of one of the compounds of the present invention in 150 mg of fractionated coconut oil, with 0.015 mg butylated hydroxytoluene (BHT) and 0.015 mg butylated hydroxyanisole (BHA), filled in a soft gelatin capsule.
- BHT butylated hydroxytoluene
- BHA butylated hydroxyanisole
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
- This application claims the benefit under 35 U.S.C. 119 (e) of U.S. provisional patent application No. 60/058,132, filed Sep. 8, 1997.
- 1. Field of the Invention
- This invention relates to 1,3-dihydroxy-20,20-dialkyl-vitamin D3 analogs, compositions comprising the analogs and methods of treatment of osteoporosis, secondary hyperparathyroidism, cancer and autoimmune diseases using such analogs.
- 2. Description of Related Art
- a. Osteoporosis
- Osteoporosis is the most common form of metabolic bone disease and may be considered the symptomatic, fracture stage of bone loss (osteopenia). Although osteoporosis may occur secondary to a number of underlying diseases, 90% of all cases appear to be idiopathic. Postmenopausal women are at risk for idiopathic osteoporosis (postmenopausal or Type I osteoporosis); another particularly high risk group for idiopathic osteoporosis is the elderly of either sex (senile or Type II osteoporosis). Osteoporosis has also been related to corticosteroid use, immobilization or extended bed rest, alcoholism, diabetes, gonadotoxic chemotherapy, hyperprolactinemia, anorexia nervosa, primary and secondary amenorrhea, transplant immunosuppression, and oophorectomy. Postmenopausal osteoporosis is characterized by fractures of the spine, while femoral neck fractures are the dominant features of senile osteoporosis.
- The mechanism by which bone is lost in osteoporotics is believed to involve an imbalance in the process by which the skeleton renews itself. This process has been termed bone remodeling. It occurs in a series of discrete pockets of activity. These pockets appear spontaneously within the bone matrix on a given bone surface as a site of bone resorption. Osteoclasts (bone dissolving or resorbing cells) are responsible for the resorption of a portion of bone of generally constant dimension. This resorption process is followed by the appearance of osteoblasts (bone forming cells) which then refill with new bone the cavity left by the osteoclasts.
- In a healthy adult subject, osteoblasts and osteoclasts function so that bone formation and bone resorption are in balance. However, in osteoporotics an imbalance in the bone remodeling process develops which results in bone being replaced at a slower rate than it is being lost. Although this imbalance occurs to some extent in most individuals as they age, it is much more severe and occurs at a younger age in postmenopausal osteoporotics, following oophorectomy, or in iatrogenic situations such as those resulting from corticosteroid therapy or the immunosuppression practiced in organ transplantation.
- Various approaches have been suggested for increasing bone mass in humans afflicted with osteoporosis, including administration of androgens, fluoride salts, and parathyroid hormone and modified versions of parathyroid hormone. It has also been suggested that bisphosphonates, calcitonin, calcium, 1,25-dihydroxy vitamin D3 and some of its analogs, and/or estrogens, alone or in combination, may be useful for preserving existing bone mass.
- Vitamin D3 is a critical element in the metabolism of calcium, promoting intestinal absorption of calcium and phosphorus, maintaining adequate serum levels of calcium and phosphorus, and stimulating flux of calcium into and out of bone. The D vitamins are hydroxylated in vivo, with the resulting 1:,25-dihydroxy metabolite being the active material. Animal studies with 1,25-(OH)2 vitamin D3 have suggested bone anabolic activity. Aerssens et al., in Calcif Tissue Int, 55:443-450 (1994), reported upon the effect of 1α-hydroxy vitamin D3 on bone strength and composition in growing rats with and without corticosteroid treatment. However, human usage is restricted to antiresorption due to the poor therapeutic ratio (hypercalciuria and hypercalcemia as well as nephrotoxicity).
- Dechant and Goa, in “Calcitriol. A review of its use in the treatment of postmenopausal osteoporosis and its potential in corticosteroid-induced osteoporosis”, Drugs Aging [NEW ZEALAND 5 (4): 300-17 (1994)], reported that 1,25-dihydroxy vitamin D3 (calcitriol) has shown efficacy in the treatment of postmenopausal osteoporosis (and promise in corticosteroid-induced osteoporosis) based upon a clinical trial in 622 women with postmenopausal osteoporosis. Patients with mild to moderate disease (but not those with more severe disease) who received calcitriol (0.25 microgram twice daily) had a significant 3-fold lower rate of new vertebral fractures after 3 years of treatment compared with patients receiving elemental calcium 1000 mg/day. In patients commencing long term treatment with prednisone or prednisolone, calcitriol 0.5 to 1.0 micrograms/day plus calcium 1000 mg/day, administered with or without intranasal calcitonin 400 IU/day, prevented steroid-induced bone loss. Overall, calcitriol was well tolerated. At recommended dosages hypercalcaemia was infrequent and mild, generally responding to reductions in calcium intake and/or calcitriol dosage. The narrow therapeutic window of calcitriol required that its use be adequately supervised, with periodic monitoring of serum calcium and creatinine levels. This study clearly identifies the key limitation of calcitriol therapy as the close proximity of therapeutic and toxic doses.
- This invention provides novel vitamin D3 derivatives which have more favorable therapeutic doses.
- b. Cancer
- Epidemiologic studies have correlated sun or UV light exposure with a lower incidence of a variety of malignancies, including breast, colon and prostate cancer. Evidence from receptor studies demonstrates that besides the classic target organs, such as intestine, kidney and bone, vitamin D receptors (VDR) are present on a wide variety of human normal and cancer cell lines and fresh tissue. Growth inhibition with vitamin D or 1,25-dihydroxycholecalciferol does not always translate into potential therapeutic efficacy in vivo. Early in vivo studies have focused on the anti-proliferative effects of 1,25-dihydroxycholecalciferol and its analogues in murine leukemia model systems where 1,25-dihydroxycholecalciferol has been shown to induce not only an anti-proliferative effect, but also a differentiating effect. Therapeutic efficacy in vivo has its limitations due to the hypercalcemia observed with high dose treatment of the parent 1,25-dihydroxycholecalciferol. As a result, a number of analogues have been developed that produce significant anti-tumor effects without hypercalcemia.
- Steinmeyer et al in U.S. Pat. No. 5,585,368 discloses Ice-25-dihydroxy-20-disubstituted vitamin D3 analogs for the treatment of hyperproliferative disorders of the-skin, malignant tumors such as leukemia, colon and breast cancers, autoimmune diseases such as diabetes and for the treatment of sebaceous gland diseases. Danielsson, C. et al in J. Cell Biochem., 63, No. 2, 199-206 (1996) disclose 20-methyl analogues of 1,25-dihydroxy vitamin D3, including 1α-25-dihydroxy-20,methyl-23 (E)-ene-cholecalciferol for the treatment of hyperproliferative disorders. This invention provides novel vitamin D3 derivatives for the treatment of hyperproliferative disorders of the skin, malignant tumors such as leukemia, colon and breast cancers, autoimmune diseases such as diabetes and for the treatment of sebaceous gland diseases which have more favorable therapeutic ratios or margins.
- c. Hyperparathyroidism
- Secondary hyperparathyroidism is routine in patients with chronic renal failure. It is established that the reduction of renal 1,25 (OH)2 vitamin D3 (calcitriol) synthesis is one of the principal mechanisms leading to the secondary hyperparathyroidism in these patients and it has been shown that calcitriol possesses direct suppressive action on PTH synthesis. Therefore, administration of calcitriol has been recommended for the treatment of secondary hyperparathyroidism in these patients. However, as described above, calcitriol has potent hypercalcemic effects giving it a narrow therapeutic window which limits its usage, especially at high doses. It would therefore be desirable to have an alternative means of treating hyperparathyroidism and repleting circulating vitamin 13 activity without incurring these undesirable hypercalcemic effects.
- This invention provides novel vitamin D3 derivatives which have more favorable therapeutic windows.
-
- wherein:
- X is hydrogen or ═CH2;
- R1 and R2 are, independently of each other, a (C1-C4)alkyl or (C1-C4)fluoroalkyl, or R1 and R12 together with C20 form a (C3-C6)cycloalkyl or (C3-C6)cyclofluoroalkyl, or R1 and R2 together form ═CH2;
- R3 and R4 are, independently of each other, a (C1-C4)alkyl or (C1-C4)fluoroalkyl, or R3 and R4 together with C25 form a (C3-C9)cycloalkyl or (C3-C9)cyclofluoroalkyl;
- A is a single or a double bond; and
- B is a single, double or triple bond;
- and prodrugs thereof, provided that:
- (i) when R1 and R2 are (C1-C4)alkyl or R1 and R2 together with C20 form a cyclopropyl group or ═CH2, R3 and R4 are (C1-C4)alkyl, trifluoromethyl or R3 and R4 together with C25 form (C3-C6)cycloalkyl and A is a single bond, then B is not a trans double bond;
- (ii) when B is a single bond, then R1 and R2 together with C20 form a (C3-C6)— cycloalkyl or (C3-C6)cyclofluoroalkyl group; and
- (iii) when R1 and R2 are (C1-C4)alkyl, R3 and R4 are (C1-C4)alkyl, X═CH2 and A is a single bond, then B is not a double bond.
- A second aspect of this invention relates to a method for treating osteoporosis or secondary hyperparathyroidism via administration of a compound of Formula (I), wherein:
- X is hydrogen or ═CH2;
- R1 and R2 are, independently of each other, a (C1-C4)alkyl or (C1-C4)fluoroalkyl, or R1 and R2 together with C20 form a (C3-C6)cycloalkyl or (C3-C6)cyclofluoroalkyl, or R1 and R2 together form ═CH2;
- R3 and R4 are, independently of each other, a (C1-C4)alkyl or (C1-C4)fluoroalkyl, or R3 and R4 together with C25 form a (C3-C9)cycloalkyl or (C3-C9)cyclofluoroalkyl;
- A is a single or a double bond; and
- B is a single, double or triple bond;
- and prodrugs thereof, in an amount therapeutically effective to restore bone density to an asymptomatic level, without inducing hypercalciuria, hypercalcemia, or nephrotoxicity.
- A third aspect of this invention relates to a method for treating cancer via administration of a compound of Formula (I), wherein:
- X is hydrogen or ═CH2;
- R1 and R2 are, independently of each other, a (C1-C4)alkyl or (C1-C4)fluoroalkyl, or R1 and R2 together with C20 form a (C3-C6)cycloalkyl or (C3-C6)cyclofluoroalkyl, or R1 and R2 together form ═CH2;
- R3 and R4 are, independently of each other, a (C1-C4)alkyl or (C1-C4)fluoroalkyl, or R3 and R4 together with C25 form a (C3-C9)cycloalkyl or (C3-C9)cyclofluoroalkyl;
- A is a single or a double bond; and
- B is a single, double or triple bond;
- and prodrugs thereof, in an amount therapeutically effective, without inducing hypercalciuria, hypercalcemia, or nephrotoxicity provided that:
- (i) when R1 and R2 are (C1-C4)alkyl or R1 and R2 together with C20 form a cyclopropyl group or ═CH2, R3 and R4 are (C1-C4)alkyl, trifluoromethyl or R3 and R4 together with C25 form (C3-C6)cycloalkyl and A is a single bond, then B is not a trans double bond;
- (ii) when B is a single bond, then R1 and R2 together with C20 form a (C3-C6)— cycloalkyl or (C3-C6)cyclofluoroalkyl group; and
- (iii) when R1 and R2 are (C1-C4)alkyl, R3 and R4 are (C1-C4)alkyl, X═CH2 and A is a single bond, then B is not a double bond.
- A fourth aspect of this invention relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a vitamin D3 analog of Formula (I).
-
- wherein:
- X is hydrogen or ═CH2;
- R1 and R2 are, independently of each other, a (C1-C4)alkyl or (C1-C4)fluoroalkyl, or R and R2 together with C20 form a (C3-C6)cycloalkyl or (C3-C6)cyclofluoroalkyl, or R1 and R2 together form ═CH2;
- R3 and R4 are, independently of each other, a (C1-C4)alkyl or (C1-C4)fluoroalkyl, or R3 and R4 together with C25 form a (C3-C9)cycloalkyl or (C3-C9)cyclofluoroalkyl;
- A is a single or a double bond; and
- B is a single, double or triple bond;
- and prodrugs thereof, provided that:
- (i) when R1 and R2 are (C1-C4)alkyl or R1 and R2 together with C20 form a cyclopropyl group or ═CH2, R3 and R4 are (C1-C4)alkyl, trifluoromethyl or R3 and R4 together with C25 form (C3-C6)cycloalkyl and A is a single bond, then B is not a trans double bond;
- (ii) when B is a single bond, then R1 and R2 together with C20 form a (C3-C6)— cycloalkyl or (C3-C6)cyclofluoroalkyl group; and
- (iii) when R1 and R2 are (C1-C4)alkyl, R3 and R4 are (C1-C4)alkyl, X═CH2 and A is a single bond, then B is not a double bond.
- A method for treating osteoporosis or secondary hyperparathyroidism via administration of a compound of Formula (I), wherein:
- X is hydrogen or ═CH2;
- R1 and R2 are, independently of each other, a (C1-C4)alkyl or (C1-C4)fluoroalkyl, or R1 and R2 together with C20 form a (C3-C6)cycloalkyl or (C3-C6)cyclofluoroalkyl, or R1 and R2 together form ═CH2;
- R3 and R4 are, independently of each other, a (C1-C4)alkyl or (C1-C4)fluoroalkyl, or R3 and R4 together with C25 form a (C3-C9)cycloalkyl or (C3-C9)cyclofluoroalkyl;
- A is a single or a double bond; and
- B is a single, double or triple bond;
- and prodrugs thereof, in an amount therapeutically effective to restore bone density to an asymptomatic level, without inducing hypercalciuria, hypercalcemia, or nephrotoxicity.
- A method for treating cancer via administration of a compound of Formula (I), wherein:
- X is hydrogen or ═CH2;
- R1 and R2 are, independently of each other, a (C1-C4)alkyl or (C1-C4)fluoroalkyl, or R1 and R2 together with C20 form a (C3-C6)cycloalkyl or (C3-C6)cyclofluoroalkyl, or R1 and R2 together form ═CH2;
- R3 and R4 are, independently of each other, a (C1-C4)alkyl or (C1-C4)fluoroalkyl, or R3 and R4 together with C25 form a (C3-C9)cycloalkyl or (C3-C9)cyclofluoroalkyl;
- A is a single or a double bond; and
- B is a single, double or triple bond;
- and prodrugs thereof, in an amount therapeutically effective, without inducing hypercalciuria, hypercalcemia, or nephrotoxicity, provided that:
- (i) when R1 and R2 are (C1-C4)alkyl or R1 and R2 together with C20 form a cyclopropyl group or ═CH2, R3 and R4 are (C1-C4)alkyl, trifluoromethyl or R3 and R4 together with C25 form (C3-C6)cycloalkyl and A is a single bond, then B is not a trans double bond;
- (ii) when B is a single bond, then R1 and R2 together with C20 form a (C3-C6)— cycloalkyl or (C3-C6)cyclofluoroalkyl group; and
- (iii) when R1 and R2 are (C1-C4)alkyl, R3 and R4 are (C1-C4)alkyl, X═CH2 and A is a single bond, then B is not a double bond.
- As used herein, the term (C1-C4) alkyl means a fully-saturated hydrocarbon radical having one to four carbon atoms; a (C1-C4) fluoroalkyl is an alkyl radical, as defined above, in which one or more hydrogen atoms attached to the carbon backbone have been substituted with one or more fluorine atoms. A (C3-C6) cycloalkyl is a cyclic saturated hydrocarbon radical having three to six ring carbon atoms; a (C3-C6) cyclofluoroalkyl is a cycloalkyl radical, as defined above, in which one or more hydrogen atoms attached to the carbon backbone have been substituted with one or more fluorine atoms. A (C3-C9) cycloalkyl is a cyclic saturated hydrocarbon radical having three to nine ring carbon atoms; a (C3-C9) cyclofluoroalkyl is a cyclic saturated hydrocarbon radical having three to nine carbon atoms in which one or more hydrogen atoms attached to the carbon backbone have been substituted with one or more fluorine atoms.
- Further as used herein, by double bond it is meant an unsaturated linkage between two adjacent carbon atoms in which two pairs of electrons are shared equally, and wherein each carbon atom bears two single-bonded substituents in either a cis (Z) or a trans (E) configuration about the double bond.
- “Pro-drugs” means any compound which releases an active parent drug according to Formula (I) in vivo when such prodrug is administered to a mammalian subject. Prodrugs of a compound of Formula (I) are prepared by modifying functional groups present in the compound of Formula (I) in such a way that the modifications may be cleaved in vivo to release the parent compound. Prodrugs include compounds of Formula (I) wherein a hydroxy group in compound (I) is bonded to any group that may be cleaved in vivo to regenerate the free hydroxyl group. Examples of prodrugs include, but are not limited to esters (e.g., acetate, formate, and benzoate derivatives), carbamates (e.g., N,N-dimethylaminocarbonyl) and ethers of hydroxy functional groups in compounds of Formula (I), and the like. Such compounds are routinely made by one of skill in the art by acylating or etherifying the hydroxy group in the parent molecule.
- A “therapeutically effective amount” means the amount of a compound that, when administered to a mammal for treating or preventing a disease, is sufficient to effect such treatment or prevention for the disease. The “therapeutically effective amount” will vary depending on the compound, the disease and its severity and the age, weight, etc., of the mammal to be treated.
- The compounds of the present invention may be generically described as 1α,25-dihydroxy-20,20-dialkyl and 1α,25-dihydroxy-20,20-dialkyl-19-nor analogs of vitamin D3.
-
- For example, a compound of the invention where X is ═CH2, R1 and R2 together form a cyclopropyl group, A is a single bond and B is a triple bond is named as 1α-25-dihydroxy-23-yne-20,21,28-cyclopropyl-cholecalciferol.
- The following Table I provides some representative examples of compounds of the present invention:
TABLE I CPD # A B R1 R2 R3 R4 X 1 — ≡ —CH2CH2— CH3 CH3 ═CH2 2 — ≡ —CH2CH2— CH3 CH3 H2 3 — ≡ —CH2CH2— CF3 CF3 ═CH2 4 — ≡ —CH2CH2— CF3 CF3 H2 5 — cis = bond —CH2CH2— CF3 CF3 ═CH2 6 — cis = bond —CH2CH2— CF3 CF3 H2 - and are named as:
- 1. 1,25-dihydroxy-23-yne-20,21,28-cyclopropyl-cholecalciferol.
- 2. 1,25-dihydroxy-23-yne-20,21,28-cyclopropyl-19-nor-cholecalciferol.
- 3. 1,25-dihydroxy-23-yne-26,27-hexafluoro-20,21,28-cyclopropyl-cholecalciferol.
- 4. 1,25-dihydroxy-23-yne-26,27-hexafluoro-20,21,28-cyclopropyl-19-nor-cholecalciferol.
- 5. 1,25-dihydroxy-23-(Z)-ene-26,27-hexafluoro-20,21,28-cyclopropyl-cholecalciferol.
- 6. 1,25-dihydroxy-23-(Z)-ene-26,27-hexafluoro-20,21,28-cyclopropyl-19-nor-cholecalciferol.
- While the broadest definition of this invention is set forth in the Summary of the Invention, certain compounds of Formula (I) are preferred.
- A preferred group of compounds are those wherein:
- A is a single or a double bond, preferably a single bond; and
- B is a triple bond.
- Another preferred group of compounds are those wherein:
- A is a double bond; and
- B is a double bond.
- Yet another preferred group of compounds are those wherein:
- A is a single or a double bond, preferably a single bond; and
- B is a cis double bond.
- Within these preferred groups of compounds, more preferred groups are those wherein:
- R1 and R2 together with C20 form a (C3-C6)cycloalkyl, preferably a cyclopropyl; and
- R3 and R4 are, independently of each other, a (C1-C4)alkyl or a (C1-C4)fluoroalkyl, preferably methyl, ethyl, trifluoromethyl, 1,1-difluoroethyl or 2,2,2-trifluoroethyl, more preferably methyl or trifluoromethyl.
- Analogs of this invention may generally be prepared by reaction and combination of fragments of Vitamin D3 molecules (see e.g., Shiuey et al., J. Org. Chem, 55:243 (1990); Wovkulich, P. M. et al., Tetrahedron, 40, 2283 (1984); Baggiolini E. B. et al J. Org. Chem., 51, 3098-3108, (1986) and Steinmeyer et al., U.S. Pat. No. 5,585,368.
- The starting materials and reagents used in preparing these compounds are either available from commercial suppliers such as Aldrich Chemical Co., (Milwaukee, Wis.), or Sigma (St. Louis, Mo.) or they can be prepared by methods known to those skilled in the art following procedures set forth in references such as Fieser and Fieser'sReagents for Organic Synthesis, Vol. 1-15 (John Wiley and Sons, 1991); March's Advanced Organic Chemistry, (John Wiley and Sons 4th Edition) and Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989).
- The starting materials and the intermediates of the reaction may be isolated and purified if desired using conventional techniques, including but not limited to filtration, distillation, crystallization, chromatography and the like. Such materials may be characterized using conventional means, including physical constants and spectral data.
- The preparation of compounds of Formula (I) and the intermediates used in their preparation is illustrated by the reaction schemes below.
-
- The coupling reaction is carried out in the presence of a strong base such as an alkyllithium like n-butyllithium in a mixture of hexane and tetrahydrofuran at −78° C. to give a trisilyl derivative of compound of Formula (I). Removal of the silyl protecting groups with tetrabutylammonium fluoride in a suitable polar organic solvent such as tetrahydrofuran provides a compound of Formula (I).
- It should be noted that although the shown intermediates have hydroxy groups typically protected as silylethers, the scope of the invention includes the use of alternative hydroxyl protecting groups known in the art as described in T. W. Greene, “Protective Groups in Organic Synthesis,” Wiley, New York (1991) and J. F. McOmie, “Protective Groups in Organic Chemistry,” Plenum Press, London (1973), together with alternative methods for deprotection.
- Synthesis of compounds of Formula (III) are known and conventional in this art. See, for example, U.S. Pat. Nos. 5,585,368 to Steinmeyer et al., 5,384,314 to Doran et al., 5,428,029 to Doran et al., 5,451,574 to Baggiolini et al.; pending U.S. patent application Serial No. 60/018,219; Shiuey et al.,J. Org. Chem., 55:243-247 (1990), Kiegel, J. et al. and Tetr. Lett., 32:6057-6060 (1991), Perlman, K. L., et al., Tetr. Lett., 32:7663-7666 (1991).
- Synthesis of compounds of Formula (II) is described in Scheme II below.
- Detailed descriptions of the synthesis of compounds of Formula (I) where R1 and R2 together form a cyclopropyl ring, X is ═CH2 or H2, A is a single bond, B is a triple bond and R3 and R4 are either methyl or trifluoromethyl are described in Examples 2, 3, 5 and 6.
- Detailed descriptions of the synthesis of compounds of Formula (I) where R1 and R2 together form a cyclopropyl ring, X is ═CH2 or H2, A is a single bond, B is a cis double bond and R3 and R4 are trifluoromethyl are described in Examples 8 and 9.
-
- As shown above, preparation of a compound of Formula (II) involves preparation of a common intermediate, 1-[(5-hydroxy)-3-alkynyl]-inden-4-ol derivative (VII), which is then converted to a compound of Formula (II) where B is either a double or a triple bond by following method (a) or method (b) respectively.
- Compound (VII) is prepared by condensation of lithium acetylide derived from a 1-(3-alkynyl)-4-tert-butyldimethylsilyloxy-7a-methyl-indene derivative (IV) with a ketone of Formula (V) where R3 and R4 are as defined in the Summary of the Invention to give a 1-[(5-hydroxy)-3-alkynyl]-4-tert-butyldimethylsilyloxy-7a-methyl-indene derivative (VI). The condensation reaction is carried out in the presence of a strong base such as n-butyllithium in an aprotic organic solvent such as tetrahydrofuran and at low temperatures ranging between −50 to −100° C. Removal of the silyl group with tetrabutylammonium fluoride in an suitable organic solvent such as tetrahydrofuran gives the 1-[(5-hydroxy)-3-alkynyl]-inden-4-ol derivative (VII).
- A detailed description of the synthesis of compounds of Formula (IV) where R1 and R2 together form a cyclopropyl ring and A is a single bond is given in Example 1. Synthesis of other compounds of Formula (IV) and alternative methods for preparing compounds of Formula (VII) have been described in copending U.S. application Ser. No. 08/857,569, published as EP 0 808,832 A2, whose disclosure is hereby incorporated by reference.
- A compound of Formula (II) where B is a triple bond and R5 is hydrogen is prepared, as shown in method (a), by oxidation of the hydroxy group at the 4-position in compound (VII) to the keto group with a suitable oxidizing agent such as pyridinium dichromate at room temperature. The oxidation reaction is carried out in a chlorinated hydrocarbon solvent such as methylene chloride, chloroform and the like. A compound of Formula (II) where W is hydrogen is converted to the corresponding compound of Formula (II) where R is trialkylsilyl, preferably trimethylsilyl, by reacting it with a suitable silylating agent such as 1-trimethylsilylimidazole in a non-alcoholic organic solvent such as tetrahydrofuran, methylene chloride, preferably methylene chloride, and the like.
- Synthesis of compounds of Formula (II) where A is a single bond, B is a triple bond, R1 and R2 together form a cyclopropyl ring, R5 is trimethylsilyl or hydrogen and R3 and R4 are methyl or trifluoromethyl are described in Examples 1 and 4.
- Alternatively, a compound of Formula (II) where B is a double bond is prepared, as shown in method (b), by partial reduction of the triple bond in compound (VII) with a suitable reducing agent to give a 3-alkene-4H-inden-4-ol of Formula (VIII). The choice of the reducing agent depends on the configuration about the double bond. If the E configuration is desired, then the reduction is carried out with lithium aluminum hydride in the presence of an alkali metal alkoxide, such as sodium methoxide, and in an aprotic organic solvent like ether or more preferably tetrahydrofuran. If the Z configuration is desired, then the reduction is carried out with Lindlar's catalyst. Compound (VIII) is then converted to a compound of Formula (II) where B is a double bond and R5 is hydrogen or a silyl group by carrying out the oxidation and silylation steps as described above. Synthesis of a compound of Formula (II) where A is a single bond, B is a cis double bond, R1 and R2 together form a cyclopropyl ring, R5 is trimethylsilyl and R3 and R4 are trifluoromethyl is described in Example 7.
-
- The starting material is reduced, preferably by catalytic hydrogenation, to give the completely saturated side chain derivative which is then oxidized to give the corresponding ketone. Condensation with a diphenylphosphine oxide as previously described in Scheme I followed by removal of the silyl protecting groups gives the desired compound. One of skill in the art will recognize that similar procedures may be used to form other compounds of the invention where R1-R4 and X may vary as described in the Summary of the Invention.
- The compounds of this invention are useful for the prevention and treatment of a variety of mammalian conditions manifested by loss of bone mass. In particular, the compounds of this invention are anabolic agents and are indicated for the prophylaxis and therapeutic treatment of osteoporosis and osteopenia in mammals without inducing hypercalciuria, hypercalcemia, or nephrotoxicity. As used herein, “hypercalciuria” is excessive calcium in the urine, in humans corresponding to an excretion of greater than about 4 mg/kg/day. This often results in nephrolithiasis (renal calculi). “Hypercalcemia” is an excessive concentration of calcium in the serum; in humans (and rats) this corresponds to greater than about 10.5 mg/dl. “Intolerable hypercalcemia”, usually occurring at serum calcium concentrations greater than about 12 mg/dl, is associated with emotional lability, confusion, delirium, psychosis, stupor, and coma.
- The compounds of this invention are expected to be useful in the treatment of Type I (postmenopausal), Type II (senile), and Type III (iatrogenic) osteoporosis, including that associated with immunosuppressive drugs used in organ transplantation, as well in the treatment of osteodystrophy due to renal dialysis and secondary hyperparathyroidism.
- Compounds of this invention are also useful in treating diseases caused by elevated levels of parathyroid hormone. In one aspect, compounds of the invention are used in treating secondary hyperparathyroidism associated with renal failure and in particular with reversing or reducing the bone loss associated with renal insufficiency. Other aspects include the treatment of renal osteodystrophy associated with late stage secondary hyperparathyroidism. Other aspects include the treatment of primary hyperparathyroidism.
- Compounds of Formula (I) are also useful in treating neoplastic diseases such as leukemia, colon cancer, breast cancer and prostate cancer.
- Compounds of Formula (I) are also useful in treating immunosuppressive and autoimmune diseases. Such diseases include, but are not limited to, multiple sclerosis, systemic lupus erythematosus, diabetes, thyroiditis and allograft rejection. In particular, compounds of Formula (I) are useful to treat diseases via modulation of the activity of the vitamin D3 receptor (VDR). The utility of these compounds is demonstrated in vivo using murine models for these diseases as is well known in the art. See, e.g., Lemire et al., Autoimmunity, 12:143-148 (1992); Lemire et. al., J. Clin. Invest., 87:1103-1107 (1991), Lemire et al., Endocrinology, 135:2818 (1994), and Lemire et al., J. Cellular Biochem., 49:26-31 (1992).
- The bone anabolic activity of the compounds of the invention was demonstrated in vivo in the ovariectomized rat model as described in detail in Example 10. The anti-cell proliferation activity of the compounds of the invention was demonstrated in vitro as described in detail in Examples 11 and 12. The parathyroid hormone suppressive activity of the compounds of the invention was demonstrated in vivo as described in detail in Example 13.
- In general, the compound of this invention may be administered in amounts between about 0.0002 and 5 μg per day, preferably from about 0.001 to about 2 μg per day, most preferably from about 0.002 to about 1 μg per day. For a 50 kg human subject, the daily dose of active ingredient may be from about 0.01 to about 250 μg, preferably from about 0.05 to about 100 μg, most preferably from about 0.1 to about 50 μg per day. In other mammals, such as horses, dogs, and cattle, other doses may be required. This dosage may be delivered in a conventional pharmaceutical composition by a single administration, by multiple applications, or via controlled release, as needed to achieve the most effective results, preferably once or twice daily by mouth. In certain situations, alternate day dosing may prove adequate to achieve the desired therapeutic response.
- The selection of the exact dose and composition and the most appropriate delivery regimen will be influenced by, inter alia, the pharmacological properties of the formulation, the nature and severity of the condition being treated, and the physical condition and mental acuity of the recipient. In the treatment of corticosteroid induced osteopenia, it is expected that the requisite dose will be greater for higher doses of corticosteroids.
- Representative delivery regimens include oral, parenteral (including subcutaneous, intramuscular and intravenous), rectal, buccal (including sublingual), pulmonary, transdermal, and intranasal, most preferably oral.
- A further aspect of the present invention relates to pharmaceutical compositions comprising as an active ingredient a compound of the present invention, in admixture with a pharmaceutically acceptable, non-toxic carrier. As mentioned above, such compositions may be prepared for parenteral (subcutaneous, intramuscular or intravenous) administration, particularly in the form of liquid solutions or suspensions; for oral or buccal administration, particularly in the form of tablets or capsules; for pulmonary or intranasal administration, particularly in the form of powders, nasal drops or aerosols; and for rectal or transdermal administration.
- The compositions may conveniently be administered in unit dosage form and may be prepared by any of the methods well-known in the pharmaceutical art, for example as described inRemington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., (1985). Formulations for parenteral administration may contain as excipients sterile water or saline, alkylene glycols such as propylene glycol, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, hydrogenated naphthalenes and the like. Formulations for nasal administration may be solid and may contain excipients, for example, lactose or dextran, or may be aqueous or oily solutions for use in the form of nasal drops or metered spray. For buccal administration typical excipients include sugars, calcium stearate, magnesium stearate, pregelatinated starch, and the like.
- Orally administrable compositions may comprise one or more physiologically compatible carriers and/or excipients and may be in solid or liquid form, including, for example, tablets, coated tablets, capsules, lozenges, aqueous or oily suspensions, solutions, emulsions, elixirs, and powders suitable for reconstitution with water or another suitable liquid vehicle before use. Tablets and capsules may be prepared with binding agents, for example, syrup, acacia, gelatin, sorbitol, tragacanth, or poly-vinylpyrollidone; fillers, such as lactose, sucrose, corn starch, calcium phosphate, sorbitol, or glycine; lubricants, such as magnesium stearate, talc, polyethylene glycol, or silica; and surfactants, such as sodium lauryl sulfate. Liquid compositions may contain conventional additives such as suspending agents, for example sorbitol syrup, methyl cellulose, sugar syrup, gelatin, carboxymethylcellulose, or edible fats; emulsifying agents such as lecithin, or acacia; vegetable oils such as almond oil, coconut oil, cod liver oil, or peanut oil; preservatives such as butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT). Liquid compositions may be encapsulated in, for example, gelatin to provide a unit dosage form.
- Preferred solid oral dosage forms include tablets, two-piece hard shell capsules and soft elastic gelatin (SEG) capsules. SEG capsules are of particular interest because they provide distinct advantages over the other two forms (see Seager, H., “Soft gelatin capsules: a solution to many tableting problems”;Pharmaceutical Technology, 9, (1985). Some of the advantages of using SEG capsules are: a) dose-content uniformity is optimized in SEG capsules because the drug is dissolved or dispersed in a liquid that can be dosed into the capsules accurately, b) drugs formulated as SEG capsules show good bioavailability because the drug is dissolved, solubilized or dispersed in an aqueous-miscible or oily liquid and therefore when released in the body produce drug dispersions of high surface area and c) degradation of drugs that are sensitive to oxidation during long-term storage is prevented because the dry shell of soft gelatin provides a barrier against the diffusion of oxygen.
- The dry shell formulation typically comprises of about 40% to 60% concentration of gelatin, about a 20% to 30% concentration of plasticizer (such as glycerin, sorbitol or propylene glycol) and about a 30 to 40% concentration of water. Other materials such as preservatives, dyes, opacifiers and flavours also may be present. The liquid fill material comprises a solid drug that has been dissolved, solubilized or dispersed (with suspending agents such as beeswax, hydrogenated castor oil or polyethylene glycol 4000) or a liquid drug in vehicles or combinations of vehicles such as mineral oil, vegetable oils, triglycerides, glycols, polyols and surface-active agents.
- The following examples are given to enable those skilled in the art to more clearly understand and to practice the present invention. They should not be considered as limiting the scope of the invention, but merely as being illustrative and representative thereof.
-
- Step 1
- Cold dimethylaluminum chloride (34.5 ml, 34.5 mmol, 1M solution in hexanes) was added dropwise to a suspension of [1R-(1α,3aβ,4α,7aα)](1,1-dimethylethyl)dimethyl-[[(octahydro-7a-methyl-1-(1-methylethenyl)-1H-inden-4-yl]oky]silane (9.25 g, 30 mmol) and paraformaldehyde (1.03 g, 34.5 mmol) in dichloromethane (90 ml) at −20° C. The reaction mixture was stirred at 10° C. for 1 h and then poured on ice and acidified with 0.1N hydrochloric acid (100 ml). After 15 min., the reaction mixture was extracted into hexanes and the extracts were washed with brine, dried over magnesium sulfate and concentrated in vacuo to give 9.67 g of a colorless gum. Flash chromatography on silica gel with 25% ethyl acetate/hexanes as the eluant gave 8.93 g of a colorless gum. 1.0 g of this material was purified by HPLC to give [1R-(1α,3aα,4α,7aα)]-4-[[(1,1-dimethylethyl)dimethylsilyl]oxy]octahydro-7a-methyl-γ-methylene-1H-indene-1-propanol (0.93 g): mp 38-40° C.; [α]25D=+26.7°; IR (CHCl3) 3630 and 1635 cm−1; 1H NMR (CDCl3) δ 0.01 (3H, s), 0.011 (3H, s), 0.80 (3H, s), 0.88 (9H, s), 1.15 (1H, m), 1.3-1.63 (5H, m), 1.65-1.76 (6H, m), 2.0 (1H, m), 2.27 (2H, m), 3.68 (2H, t, J=6.0 Hz), 4.01 (1H, s), 4.91 (1H, s), 4.95 (1H, s); MS m/z 339 (M++H, 40). Anal. Calcd. for C20H38O2Si: C, 70.94; H, 11.31; Si, 8.29. Found: C, 70.95; H, 11.62; Si, 8.30.
- Step 2
- To a mixture of [1R-(1α,3aβ,4α,7aα)]-4-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-octahydro-7a-methyl-γ-methylene-1H-indene-1-propanol (5.07 g, 15 mmol), [prepared as described in Step 1 above] and diiodomethane (13.39 g, 50 mmol) in dichloromethane (45 ml) at −10° C. was added a cold (−1° C.) solution of diethylzinc (45 ml, 45 mmol, 1 M solution in toluene). The reaction mixture was stirred at 5-7° C. for 4.25 h and then poured into a mixture of hexanes (25 ml) and 0.1 N sulfuric acid (150 ml). The product was extracted into hexanes and the extracts were washed with brine, dried over magnesium sulfate and evaporated in vacuo to give 5.34 g of a pale yellow gum. Flash chromatography on silica gel with 30% ethyl acetate/hexanes as the eluant gave 4.91 g of crude product which was further purified by HPLC (15-30 μm mesh silica, 50×50 mm column, 70 ml/min, flow rate) with 20% ethyl acetate in hexanes as eluant to give pure [1R-(1α,3aβ,4α,7aα)]-1-[4-[[1,1-dimethylethyl)dimethylsilyl]oxy]octahydro-7a-methyl-1H-inden-1-yl]cyclopropaneethanol (4.13 g): mp 65-66° C.; [α]25D=+69.17° (CHCl3, c=1.33); IR (CHCl3) 3620 cm−1; 1H NMR (CDCl3) δ 0.04 (3H, s), 0.06 (3H, s), 0.80 (1H, m), 0.22 (2H, m), 0.69 (1H, m), 0.88 (9H, s), 0.92 (2H, m), 0.94 (3H, s). 1.20-1.55 (8H, m), 1.64 (1H, br d), 1.78-1.92 (2H, m), 2.02 (1H, d, J=12 Hz), 2.30 (1H, m), 3.76 (2H, br, t of t), 3.97 (1H, s); MS m/z 353 (M++H, 70). Anal. Calcd. for C21H40O2Si: C, 71.53; H, 11.43; Si, 7.96. Found: C, 71.48; H, 11.67; Si, 7.93.
- Step 3
- [1R-(1α,3aβ,4α,7aα)]-1-[4-[[1,1-dimethylethyl)dimethylsilyl]oxy]octahydro-7a-methyl-1H-inden-1-yl]cyclopropaneethanol (1.056 g, 3.0 mmol), [prepared as described in Step 2 above] was added to a suspension of pyridinium chlorochromate (1.132 g, 5.246 mmol) and anhydrous sodium acetate (0.430 g, 5.244 mmol) in dichloromethane (15 ml) and the reaction mixture was stirred at room temperature. After 2 h, the reaction mixture was diluted with ether (35 ml), stirred for an additional 15 min., and then filtered through a pad of Florisil. The Florisil pad was washed with ether and the combined filtrate was concentrated in vacuo to give 0.93 g of a solid. Flash chromatography of the solid on a silica gel column with 10% ethyl acetate in hexanes as the eluant gave [1R-(1α,3aβ,4α,7aα)]-1-[4-[[1,1-dimethylethyl)dimethylsilyl]oxy]octahydro-7a-methyl-1H-inden-1-yl]cyclopropaneacetaldehyde (0.86 g): mp 74-75° C.; [α]25D=93.73° (CHCl3, c=1.18); IR (CHCl3) 1720 cm−1; 1H NMR (CDCl3) δ 0.00 (3H, s), 0.01 (3H, s), 0.27 (1H, m), 0.32 (1H, m), 0.50 (1H, m), 0.80 (1H, m), 0.88 (9H, s), 0.97 (3H, s), 1.03 (1H, m), 1.15 (1H, m), 1.20-1.55 (6H, m), 1.60-1.75 (2H, m), 1.80 (H, d, J=16 Hz), 1.95 (1H, d, J=12 Hz), 2.89 (1H, d, J=16 Hz), 3.97 (1H, s), 9.81 (1H, d, J=3 Hz); MS n/z 351 (M++H, 20). Anal. Calcd. for C2 1H38O2Si: C, 71.94; H, 10.92; Si, 8.01. Found: C, 71.71; H, 11.15; Si, 8.23.
- Step 4
- A solution of diethyldiazomethyl phosphonate (1.78 g, 10 mmol) in anhydrous tetrahydrofuran (6 ml) was added to a solution of potassium t-butoxide (1.234 g, 10.9 mmol) in anhydrous tetrahydrofuran (20 ml) at −70° C. After 25 min., a solution of [1R-(1α,3aβ,4α,7aα)]-1-[4-[[1,1-dimethylethyl)dimethylsilyl]oxy]octahydro-7a-methyl-1H-inden-1-yl]cyclopropaneacetaldehyde (2.103 g, 6.0 mmol), [prepared as described in Step 3 above] in tetrahydrofuran (6.0 ml) was added. After 1 h, the cooling bath was removed and the stirring was continued for an additional 1.5 h. A solution of saturated ammonium chloride (10 ml) was added. After 15 min., the reaction mixture was poured into a mixture of ether (100 ml) and saturated ammonium chloride (60 ml). The organic phase was separated and washed with brine, dried over magnesium sulfate and evaporated in vacuo to give 2.18 g of a gum. Purification by flash chromatography on silica gel column with 2.5% ethyl acetate in hexanes as the eluant gave as a crystalline solid which was slurried with methanol and filtered to give [1R-(1α,3aβ,4α,7aα)][(1,1-dimethylethyl)dimethyl[[octahydro-7a-methyl-1-[1-(2-propynyl)cyclopropyl]-1H-inden-4-yl]oxy]silane (1.77 g): mp 49-50° C.; [α]25D=58.64° (CHCl3, c=1.03); IR (CHCl3) 3307 cm−1; 1H NMR (CDCl3) δ-0.01 (3H, s), 0.00 (3H, s), 0.22 (2H, m), 0.38 (1H, m), 0.69 (1H, m), 0.87 (9H, s), 0.94 (3H, s), 0.96 (1H, m), 1.25-1.55 (7H, m), 1.64 (1H, br d, J=12 Hz), 1.75-1.90 (3H, m), 1.95 (1H, d, J=16 Hz), 1.96 (1H, s), 2.69 (1H, d, J=16 Hz), 3.98 (1H, s); MS m/z 346 (M+, 20). Anal. Calcd. for C21H38OSi: C, 76.23; H, 11.05; Si, 8.10. Found: C, 76.03; H, 10.84; Si, 8.12.
- Step 5
- n-Butyllithium (5.5 ml, 8.8 mmol, 1.6 M solution in hexanes) was added to a solution of [1R-(1α,3aβ,4α,7aα)][(1,1-dimethylethyl)dimethyl[[octahydro-7a-methyl-1-[1-(2-propynyl)cyclopropyl]-1H-inden-4-yl]oxy]silane (1.73 g, 5.0 mmol), [prepared as described in Step 4 above] in anhydrous tetrahydrofuran (18 ml) at −78° C. After 30 min., acetone (5.8 g, 100 mmol) was added and the stirring was continued for an additional 30 min. The cooling bath was removed and after 3 h additional amounts of acetone (2.9 g, 50 mmol) was added. After 1.5 h, the reaction mixture was quenched with saturated ammonium chloride (15 ml) and then poured into a mixture of ether (100 ml) and saturated ammonium chloride (60 ml). The organic layer was separated and washed with brine, dried over sodium sulfate and evaporated in vacuo to give 2.12 g of a colorless gum. Purification by flash chromatography on a silica gel column using 15% ethyl acetate in hexanes as eluant gave [1R-(1α,3aβ,4α,7aα)]-5-[1-[4-[[1,1-dimethylethyl)dimethylsilyl]oxy]octahydro-7a-methyl-1H-inden-1-yl]cyclopropyl]-2-methyl-3-pentyn-2-ol as a colorless gum (1.67 g): [α]25D=+39.09° (EtOH, c=1.036); IR (CHCl3) 3602 cm−1; 1H NMR (CDCl3) δ-0.01 (3H, s), 0.00 (3H, s), 0.20 (2H, m), 0.40 (1H, m), 0.62 (1H, m), 0.87 (9H, s), 0.93 (3H, s), 1.00 (1H, m), 1.2-1.4 (13H, m), 1.49 (6H, s), 1.62-1.95 (5H, m), 2.03 (1H, d, J=17 Hz), 2.62 (1H, d, J=17 Hz), 3.97 (1H, s); MS m/z 404 (M+, 18). Anal. Calcd. for C25H44O2Si: C, 74.28; H, 10.96; Si, 6.94. Found: C, 73.92; H, 11.22; Si, 6.87.
- Step 6
- Fluorosilicic acid (3.75 ml, 30% aqueous solution prepared as described in Pilcher, A. S. and DeShong, P.J. Org. Chem., 58, 5130 (1993)) was added to a solution of [1R-(1α,3aβ,4α,7aα)]-5-[1-[4-[[1,1-dimethylethyl)dimethylsilyl]oxy]octahydro-7a-methyl-1H-inden-1-yl]cyclopropyl]-2-methyl-3-pentyn-2-ol (0.8 g, 2.0 mmol),), [prepared as described in Step 5 above] in acetonitrile (12 ml) at 0° C. and the reaction mixture was allowed to warm to 15° C. After 3.5 h, the reaction mixture was diluted with water (10 ml) and ethyl acetate (10 ml) and then poured into a mixture of ethyl acetate (100 ml) and water (50 ml). The organic layer was separated and washed with brine, saturated sodium bicarbonate, dried over sodium sulfate and evaporated in vacuo to give a gum. Purification by flash chromatography on a silica gel column using 25% ethyl acetate in hexanes as eluant gave [1R-(1α,3aβ,4α,7aα)]octahydro-1-[1-(4-hydroxy-4-methyl-2-pentynyl)cyclopropyl]-7a-methyl-4H-inden-4-ol as a crystalline solid (0.5 g): mp 97-98° C.; [α]25D=36° (MeOH, c=1.03); IR (CHCl3) 3604,2230 cm−1; 1H NMR (CDCl3) δ 0.22 (2H, m), 0.39 (1H, m), 0.63 (1H, m), 0.97 (3H, s), 1.07 (1H, m), 1.2-1.45 (8H, m), 1.50 (6H, s), 1.79-1.90 (3H, m), 2.01 (1H, m), 2.03 (1H, d, J=17 Hz), 2.62 (1H, d, J=17 Hz), 4.06 (1H, s); MS n/z 581 (2× M++H). Anal. Calcd. for C19H30O2: C, 78.57; H, 10.41. Found: C, 78.54; H, 10.54.
- Step 7
- Pyridinium dichromate (3.30 g, 8.77 mmol) was added to a solution of [1R-(1α,3aβ,4α,7aα)]octahydro-1-[1-(4-hydroxy-4-methyl-2-pentynyl)cyclopropyl]-7a-methyl-4H-inden-4-ol (0.8 g, 2.75 mmol),), [prepared as described in Step 6 above] in dichloromethane (16 ml) and the reaction mixture was stirred at room temperature. After 3.5 h, additional amounts of dichloromethane (2.5 ml) and pyridinium dichromate (2.0 g, 5.3 mmol) were added and the stirring was continued for an additional 2.5 h. The reaction mixture was diluted, with ether (25 ml), stirred for 30 min., and then filtered through a pad of Celite. The Celite pad was washed with ether and the filtrate was concentrated in vacuo to give 0.75 g of a pale yellow gum. Purification by flash chromatography on a silica gel column using 50% ethyl acetate in hexanes as eluant gave [1R-(1α,3aβ,4α,7aα)]octahydro-1-[1-[4-hydroxy-4-methyl-2-pentynyl)cyclopropyl]-7a-methyl-4H-inden-4-one (0.70 g) as a colorless gum: [α]25D=5.5 (MeOH, c=1.2); IR (CHCl3) 3602, 2232, 1706 cm−1; 1H NMR (CDCl3) δ 0.31 (2H, m), 0.44 (1H, m), 0.62 (1H, m), 0.68 (3H, s), 1.14 (1H, m), 1.53 (6H, s), 1.73 (2H, m), 1.83 (1H, s, OH), 1.96 (1H, m), 2.04 (1H, m), 2.05 (1H, d, J=17 Hz), 2.16-2.29 (4H, m), 2.50 (1H, dd, J=7.6 Hz), 2.62 (1H, d, J=17 Hz); MS (E/I) m/z 288.2092. Anal. Calcd. for C19H28O2: C, 79.12; H, 9.78. Found: C, 78.93; H, 9.80.
- Step 8
- A solution of [1R-(1α,3aβ,7aα)]octahydro-1-[1-[4-hydroxy-4-methyl-2-pentynyl) cyclopropyl]-7a-methyl-4H-inden-4-one (0.7 g, 2.426 mmol), [prepared as described in Step 7 above] and 1-(trimethylsilyl)imidazole (2.6 ml, 17.7 mmol) in methylene chloride (15 ml) was stirred under an argon atmosphere at room temperature for 18 h and then quenched with water (10 ml). After 25 min., the reaction mixture was poured into a mixture of ether (100 ml) and water (50 ml). The organic phase was collected and the aqueous phase was re-extracted with ether. The combined organic extracts were washed with brine, dried over sodium sulfate and evaporated to give 0.82 g of a colorless oil. Purification by flash chromatography on silica gel with 20% ethyl acetate in hexane as eluant gave [1R-(1α,3aβ,7aα)]octahydro-7a-methyl-1-[1-[4-methyl-4-[trimethylsilyloxy]-2-pentynyl]cyclopropyl]-4H-inden-4-one (0.79 g, 90%) as an oil: [α]25D=−10.69° (EtOH, c=0.8151); IR (CHCl3) 2250 and 1706 cm 1; 1H NMR (CDCl3) δ 0.18 (9H, s), 0.28 (2H, m), 0.32 (1H, m), 0.62 (1H, m), 0.69 (3H, s), 1.13 (1H, m), 1.47 (3H, s), 1.48 (3H, s) 1.50-1.58 (2H, m), 1.70-1.76 (2H, m), 1.92-1.99 (1H, m), 2.00 (1H, d, J=17 Hz), 2.05 (1H, m), 2.51 (1H, m), 2.64 (1H, d, J=17 Hz); MS n/z 361 (11). Anal. Calcd. for C22H36O2Si: C, 73.28; H, 10.06; Si, 7.79. Found: C, 73.28; H, 10.10; Si, 7.79.
-
- Step 1
- n-Butyllithium (0.5 ml, 0.8 mmol, 1.6 M solution in hexane) was added to a solution of [3S-(1Z,3α,5β)]-[2-[3,5-bis[[1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylenecyclohexylidene]ethyl]diphenylphosphine oxide (0.465 g, 0.79 mmol) (see Kiegel, J. et al.Tetr. Lett., 32:6057-6060 (1991)), in anhydrous tetrahydrofuran (5.0 ml) at −78° C. The resultant deep red solution was stirred at −72° C. for 7 min., and then treated with a solution of [1R-(1α,3aβ,7aα)]octahydro-7a-methyl-1-[1-[4-methyl-4-[(trimethylsilyl)oxy]-2-pentynyl]-cyclopropyl]-4H-inden-4-one (0.18 g, 0.5 mmol) [prepared as described in Example 1] in anhydrous tetrahydrofuran (4.0 ml). After 3 h, the reaction mixture was quenched with a 1:1 mixture of 2 N Rochelle salt solution and 2 N potassium bicarbonate solution (10 ml). The reaction mixture was allowed to warm to room temperature and then poured into ethyl acetate (100 ml) and a 1:1 mixture of Rochelle salt solution and 2 N potassium bicarbonate solution (50 ml). The organic phase was separated and the aqueous phase was extracted with ethyl acetate. The combined organic extracts were washed with brine, dried over sodium sulfate and evaporated to give 0.89 g of residue. Purification by flash chromatography on silica gel with 5% ethyl acetate-hexanes as eluant gave a trisilyl intermediate (0.34 g), which was used directly in the next step.
- Step 2
- A solution of the trisilyl intermediate (0.33 g, 0.455 mmol), [prepared as described in Step 1 above] and tetrabutylammonium fluoride (3.3 ml, 3.3 mmole, 1.0 M solution in tetrahydrofuran) in anhydrous tetrahydrofuran (3.3 ml) was stirred at room temperature under argon atmosphere. After 17 h, the reaction mixture was diluted with water (10 ml). After 10 min., the reaction mixture was poured into a 1:1 mixture of brine and water and the organic phase was collected. The aqueous phase was re-extracted with ethyl acetate and the combined organic extracts were washed with brine, dried over sodium sulfate, and evaporated to give 0.19 g of a gum. Purification by flash chromatography on silica gel column with ethyl acetate as eluant gave 0.144 g of a colorless residue which was dissolved in anhydrous methyl formate (5 ml) and filtered through a 0.45 μm filter. The filtrate was evaporated at 40° C. and the residue was kept under high vacuum (0.2 mm of Hg) for 4 h to give 1,25-dihydroxy-23-yne-20,21,28-cyclopropyl-cholecalciferol (0.13 g) as a colorless foam: [α]D 23=−10.23° (EtOH, c=0.38); λmax (MeOH) 264 (ε=16859), 248 (sh, 15198), 212 (ε=15127); 1H NMR (CDCl3) δ 0.26 (2H, m), 0.41 (1H, m), 0.56 (1H, m), 0.59 (3H, s), 1.1 (1H, m), 1.40-1.49 (8H, m), 1.50 (6H, s), 1.70 (2H, m), 1.84 (1H, s, OH), 1.96 (1H, m), 2.0 (4H, m), 2.05 (1H, d, J=17 Hz), 2.31 (H, m), 2.60 (1H, d, J=17 Hz), 2.61 (H, m), 2.80 (1H, m), 4.23 (1H, br s), 4.42 (1H, br s), 4.99 (1H, s), 5.33 (1H, s), 5.98 (1H, d, J=11 Hz), 6.37 (1H, d, J=11 Hz); MS (FAB) m/z 424 (M+52).
-
- Step 1
- n-Butyllithium (0.55 ml, 0.81 mmol, 1.6 M solution in hexanes) was added to a solution of [3R-(3α,5β,Z)-3,5-bis[[1,1-dimethylethyl)dimethylsilyl]oxy]cyclohexylidene]-ethyl]diphenylphosphine oxide (0.51 g, 0.79 mmol) (see Perlman, K. L., et al.,Tetr. Lett., 32:7663-7666 (1991)), in anhydrous tetrahydrofuran (5 ml) at −78° C. under an argon atmosphere. The resultant deep red solution was stirred at −68° C. for 10 min., and then treated with a solution of [1R-(1α,3aβ,7aα)octahydro-7a-methyl-1-[1-[4-methyl-4-[trimethylsily; oxy]-2-pentynyl]cyclopropyl]-4H-inden-4-one (0.18 g, 0.5 mmol), [prepared as described in Example 1] in anhydrous tetrahydrofuran (4.0 ml). The reaction mixture was stirred at −78° C. for 4 h, then allowed to warm to 20° C. and quenched with a 1:1 mixture of 1 N Rochelle salt solution and 1 N potassium bicarbonate solution (10 ml). After 10 min., the reaction mixture was poured into ethyl acetate (100 ml) and 1:1 mixture of 1N Rochelle salt solution and 1 N potassium bicarbonate solution (50 ml). The organic phase was collected and the aqueous phase was re-extracted with ethyl acetate. The combined organic extracts were dried over sodium sulfate and evaporated to give 0.59 g of a gum. Purification by flash chromatography on silica gel column with 5% ethyl acetate in hexane as eluant gave the trisilyl intermediate (0.31 g) which was used in the next step without further purification.
- Step 2
- The trisilyl intermediate (0.30 g, 0.42 mmol), [prepared as described in Step 1 above] was dissolved in anhydrous tetrahydrofuran (3.0 ml) and treated with tetrabutylammonium fluoride (3.5 ml, 3.5 mmol, 1M solution in tetrahydrofuran). The reaction mixture was stirred at room temperature under an argon atmosphere for 48 h, then diluted with water (10 ml) and stirred for an additional 10 min. The reaction mixture was then poured into ethyl acetate (75 ml) and a 1:1 mixture of brine/water (50 ml). The organic phase was collected and the aqueous phase was re-extracted with ethyl acetate. The combined organic extracts were dried over sodium sulfate and evaporated to give 0.24 g of a residue. Purification of the residue by flash chromatography on a silica gel column using ethyl acetate as eluant gave crude product which was dissolved in methyl formate (5.0 ml) and filtered through a 0.45 μm filter. The organics were evaporated and the residue was dried under high vacuum (0.2 Torr) at room temperature for 5 h to give 1,25-dihydroxy-23-yne-20,21,28-cyclopropyl-19-nor-cholecalciferol (0.15 g) as a colorless foam: [α]D 23=+52.3° (EtOH, c=0.45); λmax (MeOH) 261 (ε=25929), 251 (E=38263), 243 (ε=22011), 227 (sh, ε=13396); 1H NMR (CDCl3) δ 0.28 (2H, m), 0.40 (1H, m), 0.55 (1H, m), 0.58 (3H, s), 1.11 (1H, m), 1.40-1.48 (2H, m), 1.50 (6H, s), 1.55-1.60 (5H, m), 1.68 (2H, m), 1.80 (2H, m), 1.90-2.05 (4H, m), 2.10 (1H, d, J=17 Hz), 2.20 (2H, m), 2.50 (1H, d, J=16 Hz), 2.60 (1H, d, J=17 Hz), 4.06 (1H, br s), 4.11 (1H, br s), 5.82 (1H, d, J=11 Hz), 6.30 (1H, d, J=11 Hz); MS (FAB) m/z 412 (M+).
-
- Step 1
- n-Butyllithium (7.5 ml, 12 mmol, 1.6 M solution in hexanes) was added to a solution of [1R-(1α,3aβ,4α,7aα)] [(1,1-dimethylethyl)dimethyl[[octahydro-7a-methyl-1-[1-(2-propynyl)cyclopropyl]-1H-inden-4-yl]oxy]silane (2.36 g, 6.25 mmol), [prepared as described in Example 1, Step 4] in anhydrous tetrahydrofuran (25 ml) at −70° C. After 45 min., hexafluoroacetone (5.8 ml, 100 mmol) that had been condensed into an addition funnel capped with a dry-ice condenser was added and stirring was continued. After 1.5 h, the reaction mixture was quenched with 2 N Rochelle salt solution (20 ml), the reaction mixture was allowed to warm to room temperature and then poured into a mixture of ethyl acetate (125 ml) and 50% brine (75 ml). The organic layer was separated and washed with brine, dried over sodium sulfate and evaporated in vacuo to give 5.8 g of a colorless gum. Purification by flash chromatography on a silica gel column using 15% ethyl acetate in hexanes as eluant gave [1R-(1α,3aβ,4α,7aα)]-5-[1-[4-[[1,1-dimethylethyl)dimethylsilyl]-oxy]octahydro-7a-methyl-1H-inden-1-yl]cyclopropyl]-1,1,1-trifluoro-2-(trifluoromethyl)-3-pentyn-2-ol (3.6 g) as a colorless oil: [α]25D=+7.69° (EtOH, c=4.0); IR (CHCl3) 3588, 2241 cm−1; 1H NMR (CDCl3) δ-0.04 (6H, s), 0.19 (1H, m), 0.28 (1H, m), 0.36 (1H, m), 0.70 (1H, m), 0.86 (9H, s), 0.93 (3H, s), 1.00 (1H, q, J=11 Hz), 1.2-1.59 (7H, m), 1.64-1.92 (4H, m), 2.06 (1H, d, J=17 Hz), 2.75 (1H, d, J=17 Hz), 3.13 (1H, s, OH), 3.96 (1H, s); MS m/z 512 (M+, 18). Anal. Calcd. for C25H38F6O2Si: C, 58.57; H, 7.47; F, 22.24; Si, 5.48. Found: C, 58.39; H, 7.57; F, 22.34; Si, 5.41.
- Step 2
- Fluorosilicic acid (6.0 ml, 30% aqueous solution prepared as described in Pilcher, A. S. and DeShong, P.J. Org. Chem., 58, 5130 (1993)) was added to a solution of [1R-(1α,3aβ,4α,7aα)]-5-[1-[4-[[11,1-dimethylethyl)dimethylsilyl]oxy]octahydro-7a-methyl-1H-inden-1-yl]cyclopropyl]-1,1,1-trifluoro-2-(trifluoromethyl)-3-pentyn-2-ol (1.24 g, 2.40 mmol), [prepared as described in Step 1 above] in acetonitrile (18 ml) and the reaction mixture was stirred at room temperature under an argon atmosphere. After 2.5 h, the reaction mixture was poured into a mixture of ethyl acetate (100 ml) and saturated sodium bicarbonate (50 ml). The organic layer was separated and washed with brine, dried over sodium sulfate and evaporated in vacuo to give 0.9 g of a partially crystalline solid. Purification by flash chromatography on a silica gel column using 25% ethyl acetate in hexanes as eluant gave [1R-(1α,3aβ,4α,7aα)]-octahydro-7a-methyl-1-[1-[5,5,5-trifluoro-4-hydroxy-4-(trifluoromethyl)-2-pentynyl]-cyclopropyl]-4H-inden-4-ol as crystalline solid (0.65 g): mp 96-970C; [α]25D=25.39° (EtOH, c=0.957); IR (CHCl3) 3590, 2266, 2241 cm−1; 1H NMR (CDCl3) δ 0.22 (1H, m), 0.32 (1H, m), 0.42 (1H, m), 0.71 (1H, m), 0.98 (3H, s), 1.04 (1H, m), 1.26-1.33 (2H, m), 1.40-1.60 (6H, m), 1.84-1.98 (4H, m), 2.01 (H, d, J=17 Hz), 2.76 (1H, d, J=17 Hz), 3.86 (1H, s, OH), 4.08 (1H, s); MS m/z 397 (M+−H). Anal. Calcd. for C19H24F6O2: C, 57.28; H, 6.07; F, 28.61. Found: C, 57.34; H, 5.97; F, 28.66.
- Step 3
- To a stirred solution of [1R-(1α,3aβ,4α,7aα)]octahydro-7a-methyl-1-[5,5,5-trifluoro-4-hydroxy-4-(trifluoromethyl)-2-pentynyl]cyclopropyl]-4H-inden-4-ol (0.66 g, 1.65 mmol), [prepared as described in Step 2 above] in methylene chloride (14 ml) was added pyridinium dichromate (4.0 g, 10.63 mmol) and the reaction mixture was stirred at room temperature for 4 h. Additional amounts of pyridinium dichromate (0.5 g, 1.32 mmol) was added and the stirring was continued for 30 min. Diethyl ether (25 ml) was added and the reaction mixture was filtered over Celite pad, and the Celite pad was then washed with diethyl ether. The combined filtrate and washings were washed with 1N potassium bicarbonate (100 ml), followed by a 1:1 mixture of brine/water. The aqueous washings were back-extracted with ethyl acetate and the combined organic extracts were dried over sodium sulfate and evaporated to give 0.64 g of partially crystalline material. Flash chromatography on silica gel column with 25% ethyl acetate in hexanes as the eluant gave [(1R-(1α,3aβ,7aα)]octahydro-7a-methyl-1-[1-[5,5,5-trifluoro-4-hydroxy-4-(trifluoromethyl)-2-pentynyl]cyclopropyl]-4H-inden-4-one (0.56 g, 86%) as colorless crystals. Crystallization of 65 mgs of the product from 50% ether in hexane gave [(1α,3aβ,7aα)]octahydro-7a-methyl-1-[1-[5,5,5-trifluoro-4-hydroxy-4-(trifluoromethyl)-2-pentynyl]cyclopropyl]-4H-inden-4-one (51 mg) as colorless needles: mp 145-146° C.; [α]26 D=−8.52° (EtOH, c=0.704); IR (CHCl3) 3588, 2268, 2242, and 1707 cm−1; 1H NMR(CDCl3) δ 0.30 (1H, m), 0.38 (1H, m), 0.45 (1H, m), 0.68 (3H, s), 1.13 (1H, q, J=14 Hz), 1.55 (2H, m), 1.73 (2H, m), 1.95 (1H, m), 2.11-2.31 (4H, m), 2.13 (1H, d, J=17 Hz), 2.50 (1H, m), 2.75 (1H, d, J=17 Hz), 3.88 (1H, s, OH); MS m/z 396. Anal. Calcd for C19H22F6O2: C, 57.47; H, 5.59; F, 28.76. Found: C, 57.60, H, 5.65; F, 28.66.
-
- Step 1
- n-Butyllithium (0.52 ml, 0.81 mmol, 1.6 M solution in hexane) was added to a stirred solution of [3S-(1Z,3α,5β)]-[2-[3,5-bis[[1,1-dimethylethyl)dimethylsilyl]oxy]-2-methylene cyclohexylidene]ethyl]diphenylphosphine oxide (0.475 g, 0.81 mmol) in anhydrous tetrahydrofuran (5.0 ml) at −78° C. The resultant deep red solution was stirred at −78° C. under argon for 8 min and then treated with a solution of [1R-(1α,3aβ,7aα)]octahydro-7a-methyl-1-[1-[5,5,5-trifluoro-4-hydroxy-4-(trifluoromethyl)-2-pentynyl]cyclopropyl]-4H-inden-4-one (0.16 g, 0.4 mmol), [prepared as described in Example 4] in anhydrous tetrahydrofuran (2.0 ml). After 3 h, the reaction mixture was allowed to warm to 10° C. and then quenched with a 1:1 mixture of 1 N Rochelle salt solution and 1 N potassium bicarbonate solution (10 ml). After 10 min., the reaction mixture was poured into ethyl acetate (100 ml) and a 1:1 mixture of 1 N Rochelle salt solution and 1 N potassium bicarbonate solution (50 ml). The organic phase was collected and the aqueous phase was re-extracted with ethyl acetate. The combined organic extracts were dried over sodium sulfate and evaporated to give 0.55 g of a gum. Purification by flash chromatography on silica gel column with 20% ethyl acetate in hexane as eluant gave 0.15 g of the trisilyl intermediate as colorless gum, which was used without purification in the next step.
- Step 2
- Tetrabutylammonium fluoride (2.5 ml, 2.5 mmol, 1M solution in tetrahydrofuran) was added to a solution of the trisilyl intermediate (0.145 g, 0.19 mmol) in anhydrous tetrahydrofuran (3.0 ml) and the reaction mixture was stirred at room temperature under an argon atmosphere. After 19 h, the reaction mixture was diluted with water (10 ml), stirred for an additional 10 min. and then poured into a mixture of ethyl acetate (75 ml) and a 1:1 mixture of brine/water (50 ml). The organic phase was collected and the aqueous phase was re-extracted with ethyl acetate. The combined organic extracts were dried over sodium sulfate and evaporated to give 0.16 g of residue. Purification by flash chromatography on silica gel column with ethyl acetate as eluant gave a solid which was dissolved in methyl formate (2.0 ml) and filtered through a 0.45 μm filter. The filtrate was evaporated at 40° C. and kept under high vacuum at room temperature for 6 h to give 1,25-dihydroxy-23-yne-26,27-hexafluoro-20,21,28-cyclopropyl-cholecalciferol (93 mgs) as a colorless foam: [α]D 25=−1.12 (EtOH, c=0.50); λmax (MeOH) 264 (ε=16762), 247 (sh, ε=14746), 213 (ε=13727); 1H NMR (CDCl3) δ 0.28 (1H, m), 0.35 (1H, m), 0.41 (1H, m), 0.59 (3H, s), 0.64 (1H, m), 1.09 (1H, m), 1.40-1.60 (7H, m), 1.65-1.78 (2H, m), 1.90-2.05 (5H, m), 2.18 (2H, d, J=17 Hz), 2.31 (1H, dd, J=14, 7 Hz), 2.63 (1H, d, J=14 Hz), 2.73 (1H, d, J=17 Hz), 2.85 (1H, m), 3.45 (1H, s, OH), 4.23 (1H, br s), 4.43 (1H, br s), 5.00 (1H, s), 5.32 (1H, s), 6.00 (1H, d, J=11 Hz), 6.37 (1H, d, J=11 Hz); MS (FAB) m/z 532 (M+50).
-
- Step 1
- n-Butyllithium (0.5 ml, 0.80 mmol, 1.6 M solution in hexane) was added to a stirred solution of [3R-(3α,5β,Z)-3,5-bis[[1,1-(dimethylethyl)dimethylsilyl]oxy]cyclohexylidene]-ethyl]diphenylphosphine oxide (0.45 g, 0.79 mmol) in anhydrous tetrahydrofuran (5.0 ml) at −78° C. The resultant deep red solution was stirred at −78° C. under argon for 8 min., and then treated with a solution of [1R-(1α,3aβ,7aα)]octahydro-7a-methyl-1-[5,5,5-trifluoro-4-hydroxy-4-(trifluoromethyl)-2-pentynyl]cyclopropyl]-4H-inden-4-one (0.16 g, 0.40 mmol), [prepared as described in Example 4 above] in anhydrous tetrahydrofuran (3.0 ml). The reaction mixture was stirred at −78° C. for 3 h, then allowed to warn to 10° C., and quenched with a 1:1 mixture of 1 N Rochelle salt solution and 1 N potassium bicarbonate solution (10 ml). After 10 min., the reaction mixture was poured into ethyl acetate (100 ml) and a 1:1 mixture of 1 N Rochelle salt solution and 1 N potassium bicarbonate solution (50 ml). The organic phase was collected and the aqueous phase was re-extracted with ethyl acetate. The combined organic extracts were dried over sodium sulfate and evaporated to give 0.54 g of residue. Purification by flash chromatography on a silica gel column with 20% ethyl acetate in hexane as eluant gave 0.15 g of trisilyl intermediate as a colorless gum, which was used without further purification in the next step.
- Step 2
- Tetrabutylammonium fluoride (2.5 ml, 2.5 mmol, 1M solution in tetrahydrofuran) was added to a solution of above trisilyl intermediate (0.15 g, 0.20 mmol) in anhydrous tetrahydrofuran (3.0 ml). The reaction mixture was stirred under argon at room temperature for 40 h, then diluted with water (10 ml) and poured into ethyl acetate (75 ml) and a 1:1 mixture of brine/water (50 ml). The organic phase was collected and the aqueous phase was re-extracted with ethyl acetate. The combined organic extracts were dried over sodium sulfate and evaporated to give 0.10 g of crude product. Purification by flash chromatography on a silica gel column with ethyl acetate as eluant gave a residue, which was dissolved in methyl formate (5.0 ml), filtered through a 0.45 μm filter. The filtrate was evaporated at 40° C. and dried under high vacuum (0.2 Torr) at room temperature for 6 h to give 1,25-dihydroxy-23-yne-26,27-hexafluoro-20,21,28-cyclopropyl-19-nor-cholecalciferol (95 mg) as a colorless foam: [α]D 23=+36.20° (EtOH, c=0.32); λmax (MeOH) 243 (ε=31322), 251 (ε=37316), 260 (ε=25430) nm; IR(CHCl3) 3603, 2242 cm−1; 1H NMR (CDCl3) δ 0.28 (1H, m), 0.35 (I H, m), 0.42 (1H, m), 0.60 (3H, s), 0.65 (1H, m), 1.10 (1H, m), 1.40-1.72 (9H, m), 1.80 (1H, m), 1.97 (4H, m), 2.19 (1H, d, J=17 Hz), 2.49 (1H, m), 2.72 (1H, d, J=17 Hz), 2.75 (2H, m), 3.40 (1H, br s, OH), 4.05 (1H, br, s), 4.12 (1H, br s), 5.82 (1H, d, J=1 Hz), 6.30 (1H, d, J=11 Hz); MS (FAB) n/z 520 (M+80).
-
- Step 1
- A solution of [1R-(1α,3aβ,4α,7aα)]octahydro-7a-methyl-1-[1-[5,5,5-trifluoro-4-hydroxy-4-(trifluormethyl)-2-pentynyl]cyclopropyl]-4H-inden-4-ol (1.195 g) in ethyl acetate (12 ml), hexane (30.0 ml), absolute ethanol (1.2 ml), and quinoline (60 ml) was hydrogenated over Lindlar's catalyst (240 mg) at atmospheric pressure and room temperature. After 2.0 h, the reaction mixture was filtered through a pad of Celite. The Celite pad was washed with ethyl acetate and the combined filtrates were washed with 1.0 N hydrochloric acid (50 ml), brine, dried over magnesium sulfate and evaporated to give 1.16 g of a colorless gummy residue. The residue was purified by flash chromatography on a silica gel column with 40% ethyl acetate in hexanes as eluant to give 1.09 g of a colorless gum which was triturated with hexane to give [1R-[1α(Z),3aβ,4α,7aα]]octahydro-7a-methyl-1-[1-[5,5,5-trifluoro-4-hydroxy-4-(trifluormethyl)-2-pentenyl]cyclpropyl]-4H-inden-4-ol (84 mg): mp 99-100° C.; [α]D 25+24.49° (MeOH, c=1.03); IR (CHCl3) 3619, 3569, 1659 cm−1; 1H NMR (CDCl3) δ 0.09 (1H, m), 0.23 (1H, m), 0.34 (1H, m), 0.67 (1H, m), 1.00 (3H, s), 1.11 (1H, m), 1.19-1.30 (2H, m), 1.37-1.56 (6H, m), 1.76-1.88 (3H, m), 2.03 (1H, d, J=16 Hz), 2.17 (1H, ddd, J=16, 7, 6 Hz), 2.95 (1H, ddd, J=16, 7, 6), 3.13 (1H, s, OH), 4.06 (1H, s), 5.40 (1H, d, J=12 Hz), 6.10 (1H, ddd, J=12, 7, 6 Hz); MS m/z 400 (M+, 10). Anal. Calcd for C19H26F6O2: C, 56.99; H, 6.55; F, 28.47. Found: C, 57.10; H, 6.57; F, 28.31.
- Step 2
- Pyridinium dichromate (3.3 g, 8.7 mmol) was added to a stirred solution of [1R-[1α(Z),3aβ,4α,7aα]]octahydro-7a-methyl-1-[1-[5,5,5-trifluoro-4-hydroxy-4-(trifluormethyl)-2-pentenyl]cyclpropyl]-4H-inden-4-ol (1.00 g, 2.5 mmol) in dichloromethane (25 ml) and the resultant heterogeneous mixture was stirred at room temperature. After 5 h, the reaction mixture was diluted with diisopropyl ether (30 ml), stirred for an additional 15 min., and then filtered through a pad of Celite. The filtrate was evaporated to give 0.984 g of a pale yellow solid. Purification by flash chromatography on a silica gel column with 30% ethyl acetate in hexanes as eluant, gave 0.84 g of a colorless solid. The solid was dissolved in dichloromethane (4 ml) and filtered through a 0.45 mm filter (Millex-HV). The filtrate was diluted with hexane (7.0 ml) and then concentrated to about 6 ml and left at −2° C. overnight. The solid was filtered off to give [1R-[1α(Z),3aβ,7aα]]octahydro-7a-methyl-1-[1-[5,5,5-trifluoro-4-hydroxy-4-(trifluoromethyl)-2-pentenyl]cyclopropyl]-4H-inden-4-one (0.8 g) as colorless crystals: mp 124-125° C.; [α]D 25−2.6° (EtOH, c=1.00); IR (CHCl3) 3568, 1706 cm−1; 1H NMR (CDCl3) δ 0.15 (1H, m), 0.36 (2H, m), 0.60 (1H, m), 0.65 (3H, s), 1.15 (1H, m), 1.50-1.80 (4H, m), 1.85-2.3 (4H, m), 2.45 (1H, dd, J=7.6, 6.8 Hz), 2.91 (1H, ddd, J=16, 7.6, 5.9 Hz), 2.98 (1H, s, OH), 5.42 (1H, d, J=12 Hz), 6.10 (1H, ddd, J=12, 7.6, 6.8 Hz). MS m/z 398 (M+, 22). Anal. Calcd for C19H24F6O2: C, 57.28; H, 6.07; F, 28.61. Found: C, 57.39; H, 6.01; F, 28.75.
- Step 3
- A solution of [1R-[1α(Z),3aβ,7aα]]octahydro-7a-methyl-1-[1-[5,5,5-trifluoro-4-hydroxy-4-(trifluoromethyl)-2-pentenyl]cyclopropyl]-4H-inden-4-one (0.75 g, 1.88 mmol) and 1-(trimethylsilyl)imidazole (2.6 ml, 17.75 mmol) in dichloromethane (20 ml) was stirred under argon for 7 hr and then diluted with water (10 ml). After stirring for 15 min., the reaction mixture was poured into dichloromethane (60 ml) and water (50 ml). The organic phase was collected and the aqueous phase was re-extracted with dichloromethane. The combined organic extracts were washed with water, dried over magnesium sulfate and evaporated to give 0.87 g of a partially crystalline solid. Purification by flash chromatography on a silica gel with 20% ethyl acetate in hexanes as eluant gave 0.83 g of colorless crystals. The crystals were dissolved in ether (5 ml), filtered through a 0.45 mm filter (Millex-HV) and the filtrate was diluted with hexane (5 ml). The ether was evaporated and the solution was left at −1° C. overnight. Filtration of the solid gave [1R-[1α(Z),3aβ,7aα]]octahydro-7a-methyl-1-[1-[5,5,5-trifluoro-4-(trifluormethyl)-4-[(trimethylsilyl)oxy]-2-pentenyl]cyclopropyl]-4H-inden-4-one (0.80 g) as colorless crystals: mp 70-71° C.; [α]D 25+0.9° (MeOH, c=1.00); IR (CHCl3) 1706 cm−1; 1H NMR (CDCl3) δ 0.11 (1H, m); 0.22 (9H, s), 0.32 (2H, m), 0.65 (1H, m), 0.69 (3H, s), 1.12 (1H, in), 1.50-1.73 (4H, m), (1.90-2.30 (7H in), 2.47 (1H, dd, J=17, 7 Hz), 2.94 (1H, ddd, J=12, 7, 6 Hz), 5.41 (1H, d, J=12 Hz), 6.05 (1H, ddd, J=12, 7, 6 Hz). MS m/z 471 (M++H, 100). Anal. Calcd for C22H32F6O2Si: C, 56.15; H, 6.85; F, 24.22; Si, 5.97. Found: C, 56.26; H, 6.72; F, 24.29; Si, 5.80.
-
- Step 1
- n-Butyllithium (0.5 ml, 8 mmol, 1.6 M solution in hexanes) was added to a solution of [3S-(1Z,3α,5β)]-2-[3,5-bis[[1,1-dimethylethyl)dimethylsilyl]oxy-2-methylenecyclohexylidene]ethyl]diphenylphosphine oxide (0.47 g, 0.8 mmol) in anhydrous tetrahydrofuran (4 ml) at −78° C. The resulting deep red solution was stirred at −78° C. for 7 minutes and then treated with a solution of [1R-1α(Z),3aβ,7aα]octahydro-7a-methyl-1-[1-[5,5,5-trifluoro-4-(trifluoromethyl)-4-[trimethylsilyl)oxy]-2-pentenyl]cyclopropyl]-4H-inden-4-one (0.19 g, 0.4 mmol) in anhydrous tetrahydrofuran (3 ml). After 2 h, the reaction mixture was allowed to warm to −10° C. and then quenched with a 1:1 mixture of 2 N Rochelle salt solution and 2 N potassium bicarbonate solution (5.0 ml). After 20 min., the reaction mixture was poured into a mixture of ethyl acetate (60 ml) and a 1:1 mixture of 2 N Rochelle salt solution and 2 N potassium bicarbonate solution (50 ml). The organic phase was collected and the aqueous phase was re-extracted with ethyl acetate. The combined organic extracts were washed with 50% brine (100 ml), dried over sodium sulfate and evaporated to give a gum. Purification by flash chromatography on a silica gel column with 20% ethyl acetate in hexanes as eluant gave 0.11 g of the trisilyl intermediate as colorless gum, which was without further purification in the next step.
- Step 2
- Tetrabutylammonium fluoride (3.0 ml, 3.0 mmol, 1.0 M solution in tetrahydrofuran) was added to a solution of the trisilyl intermediate (0.11 g) in tetrahydrofuran {3 ml) and the reaction mixture was stirred at room temperature. After 17 h, the reaction mixture was diluted with water (5 ml), stirred for additional 15 min., and then poured into a mixture of ethyl acetate (50 ml) and 50% brine (40 ml). The organic phase was collected and the aqueous phase was re-extracted with ethyl acetate. The combined organic extracts were washed with water, dried over sodium sulfate and evaporated to give 86 mg of a gum. Purification by flash chromatography on a silica gel column with ethyl acetate as eluant gave a gum, which was dissolved in anhydrous methyl formate (7 ml), filtered through a 0.4 gm filter, and evaporated to give 1,25-dihydroxy-23-(Z)-ene-26,27-hexafluoro-20,21,28-cyclopropyl-cholecalciferol (69 mg) as a colorless foam: [α]D 25=−4.0° [MeOH, c=0.35); λmax (MeOH) 265 (ε 15837), 211 (ε=14458) nm; IR (CHCl3) 3598, 1651 cm−1; 1H NMR (CDCl3) δ 0.11 (1H, m), 0.29 (2H, m), 0.60 (3H, s), 0.61 (1H, m), 1.10 (1H, m), 1.21-1.35 (1H, m), 1.50 (6H m), 1.70 (2H, m), 1.90 (2H, m), 2.00 (3H, m), 2.30 (2H, m), 2.60 (1H, d, J=12 Hz), 2.85 (2H, m), 2.90 (1H, s, OH), 4.22 (1H, s), 4.42 (1H, s), 4.99 (1H, s), 5.32 (1H, s), 5.42 (1H, d, J=12 Hz), 5.99 (1H, d=11 Hz), 6.10 (1H, ddd, J=12, 7, 6), 6.36 (1H, d, J=11 Hz); MS (FAB) m/z 535 (M++H).
-
- Step 1
- n-Butyllithium (0.32 m, 0.5 mmol, 1.6 M solution in hexanes) was added to a solution of [3R-(3α,5β,Z)]-3,5-bis[[1,1-dimethylethyl) dimethyl-silyl]oxy]cyclohexylidene]ethyl} diphenylphosphine oxide (0.285 g, 0.5 mmol) in anhydrous tetrahydrofuran (3 ml) at −78° C. The resulting deep red solution was stirred at −78° C. for 6 minutes and then treated with [1R-1α((Z),3aβ,7aα]]octahydro-7a-methyl-1-[1-[5,5,5-trifluoro-4-(trifluoromethyl)-4-[trimethylsilyl)oxy]-2-pentenyl]cyclopropyl]-4H-inden-4-one (0.12 g, 0.25 mmol) in anhydrous tetrahydrofuran (2 ml). After 3.0 h, the reaction mixture was allowed to warm to 15° C. and quenched with 1:1 mixture of 2 N Rochelle salt solution and 2 N potassium bicarbonate solution (5 ml). After 20 min., the reaction mixture was diluted with ethyl acetate (15 ml), poured into a mixture of ethyl acetate (50 ml) and a 1:1 mixture of 2 N Rochelle salt solution and 2 N potassium bicarbonate solution (50 ml). The organic phase was collected and the aqueous phase was re-extracted with ethyl acetate. The combined organic extracts were washed with 50% brine, dried over sodium sulfate and evaporated to give 0.58 g of a gum. Purification by flash chromatography on a silica gel column with 20% ethyl acetate in hexanes as eluant, gave 0.18 g of the trisilyl intermediate as a colorless gum, which was without further purification in the next step.
- Step 2
- Tetrabutylammonium fluoride (3.0 ml, 3.0 mmol, 1.0 M solution in tetrahydrofuran) was added to a solution of the trisilyl intermediate (0.18 g) in tetrahydrofuran (3 ml) and the reaction mixture was stirred at room temperature. After 42 h, the reaction mixture was diluted with water (5 ml), stirred for an additional 15 min., and then poured into a mixture of ethyl acetate (50 ml) and 50% brine (40 ml). The organic phase was collected and the aqueous phase was re-extracted with ethyl acetate. The combined organic extracts were washed with water, dried over sodium sulfate and evaporated to give 0.12 g of a gum. Purification by flash chromatography on a silica gel column with ethyl acetate as eluant gave a gum, which was dissolved in anhydrous methyl formate (8 ml), filtered through a 0.4 μm filter, and evaporated to give 1,25-dihydroxy-23-(Z)-ene-26,27-hexafluoro-20,21,28-cyclopropyl-19-nor-cholecalciferol (98 mg) as a colorless foam: [α]D 25+47.4° [MeOH, c=0.35); λmax (MeOH) 260 (E 28200), 251 (ε=41760), 243 (ε=34747), 235 (sh, ε=23594) nm; IR (CHCl3) 3603 cm−1; 1H NMR (CDCl3) δ 0.12 (1H, m), 0.32 (2H, m), 0.60 (3H, s), 0.62 (1H, m), 1.14 (1H, m), 1.35 (1H, m), 1.41 (2H m), 1.52 (4H, m), 1.70 (2H, m), 1.82 (1H, m), 1.88-2.00 (2H, m), 2.04 (2H, m), 2.23 (3H, m), 2.47 (1H, d, J=12 Hz), 2.82 (3H, m), 2.96 (1H, s, OH), 4.04 (1H, s), 4.12 (1H, s), 5.42 (1H, d, J=12 Hz), 5.82 (1H, d=11 Hz), 6.12 (1H, ddd, J=12, 7, 6), 6.30 (1H, d, J=11 Hz); MS (EI) m/z 522 (M, 60).
- Step 1
- [1R-(1α,3aβ,4α,7aα)]-Octahydro-1-[1-(4-hydroxy-4-methylpentyl)cyclopropyl]-7a-methyl-4H-inden-4-ol
- A solution of 250 mg (0.86 mmol) of [1R-(1α,3aβ,4α,7aα)]octahydro-1-[1-(4-hydroxy-4-methyl-2-pentynyl)-cyclopropyl]-7a-methyl-4H-inden-4-ol (Ro 27-3152) in 4.0 mL of ethyl acetate, 10 mL of hexane, 0.5 mL of ethanol, and 20 μL of quinoline was hydrogenated over 75 mg of Lindlar's catalyst (5% Pd+3.5% Pb on CaCO3) at room temperature and atmospheric pressure for 2.5 hrs. The mixture was diluted with 50 mL of ethyl acetate and filtered over a pad of Celite, which was washed with 3×20 mL of ethyl acetate. The combined filtrate and washings were washed with 50 mL of 0.1N HCl then 50 mL of water, dried (Na2SO4) and evaporated to give 244 mg of a colorless gum. Flash chromatography on 50 g of silica gel (40-65 μm; 3.5 cm diameter column) with 50% ethyl acetate, taking 12-mL fractions gave, after evaporation of fractions 10-18, 230 mg of a colorless gum. 1H NMR (CDCl3) indicated it to be a mixture of the title compound and the 23,24 (Z)-ene product. The mixture was dissolved in 25 mL of CH2Cl2 and hydrogenated with 40 mg of [1,4-bis(diphenylphosphino) butane] (1,5-cyclooctadiene)-rhodium (1) tetrafluoroborate as catalyst in the presence of 1 drop of mercury in a Parr hydrogenator at room temperature and 50 psi for 3 hrs. After dilution with 30 mL of CH2Cl2, the mixture was filtered over a pad of Celite, which was washed with 3×40 mL of ethyl acetate. The filtrate and washings were evaporated to give an orange-colored gum, which was purified by flash chromatography on 45 g of silica gel (40-65 μm mesh; 3.5 cm diameter column) with 50% ethyl acetate in hexanes as eluent, taking 12-mL fractions. Fractions 13-17 were combined and evaporated to give a partially crystalline solid, which was triturated with hexane to give 204 mg of the title compound as colorless crystals, mp 126-128° C.; [α]D 25+42.6° (MEOH, c=0.3); IR 3611 cm−1; 1H NMR (CDCl3) δ-0.06 (1H, m) 0.18 (2H, m), 0.54 (1H, m), 0.59 (1H, m), 0.98 (3H, m), 1.21 (6H, s), 1.2-1.6 (15H, m), 1.75-2.10 (5H, m), 4.06 (1H, s); MS (+FAB) m/z (295, M++1, 10). Anal. Calcd for C19H34O2: C, 77.50; H, 11.64. Found C: 77.40; H, 11.89.
- Step 2
- [1R-(1α,3aβ,7aα)]-Octahydro-7a-methyl-1-[1-[5-methyl-5-[(trimethylsilyl)oxy]pentyl]cyclopropyl]-4H-inden-4-one
- To a stirred solution of 190 mg (0.64 mmol) of [1R-(1α,3aβ,4α,7aα)]-octahydro-1-[1-(4-hydroxy-4-methylpentyl)cyclopropyl]-7a-methyl-4H-inden-4-ol (Ro 27-5155) in 8.0 mL of CH2Cl2 was added 2.0 g (5.3 mmol) of pyridinium dichromate and the mixture was stirred at room temperature for 5.0 hrs. It was diluted with 20 mL of diisopropyl ether, stirred for 15 minutes and filtered over a pad of Celite, which was washed with 4×25 mL of diisopropyl ether. Evaporation of the filtrate and washings gave 184 mg of a pale yellow gum, which was purified by flash chromatography on 45 g of silica gel (40-65 μm mesh; 3.5 cm diameter column) with 45% of ethyl acetate on hexanes as eluent taking 12-mL fractions. Fractions 19-25 were combined and evaporated to give 158 mg of a colorless gum. The latter was dissolved in 5.0 mL of CH2Cl2 and treated with 1.0 μL (6.8 mmol) of 1-trimethylsilylimidazole and the mixture was stirred at room temperature for 2.0 hrs. It was diluted with 15 mL of water and 15 mL of CH2Cl2, stirred for a further 15 mins, and poured into a mixture of 40 mL of CH2Cl2 and 20 mL of 10% brine. The organic phase was separated and the aqueous phase was re-extracted with 3×50 mL of CH2Cl2. The combined organic extracts were washed with 3×60 mL of 10% brine, dried (Na2SO4) and evaporated to give 180 mg of a colorless gum, which was purified by flash chromatography on 45 g of silica gel (40-65 Mm mesh; 3.5 cm diameter column) with 15% ethyl acetate in hexanes as eluent, taking 12-mL fractions. Fractions 10-14 were combined and evaporated to give 137 mg of a colorless gum, which was further purified by HPLC on silica gel (15-30 μm mesh; 50 mm×50 cm column; 70 mL/min) with 7.5% ethyl acetate in hexanes as eluent. The material eluting at 18.5 minutes was collected and evaporated to give 114 mg of the title compound as a gum, which solidified on keeping at 0° C. overnight; [α]D 25+7.8° (CHCl3, c=0.41); IR 1707 cm−1; 1H NMR (CDCl3) δ 0.00 (1H, m), 0.11 (9H, s), 0.20 (2H, m), 0.63 (2H, m), 0.68 (3H, s), 1.01 (1H m), 1.21 (6H, s), 1.30-1.72 (7H, m), 1.90-2.10 (3H, m), 2.15-2.3 (5H, m), 2.5 (1H, m); MS (+FAB) m/z 349.252 (M+−15, 48).
- Step 3
- 1,25-Dihydroxy-20,21,28-cyclopropyl-cholecalciferol
- To a cooled (−78° C.), stirred solution of 335 mg (0.57 mmol) of [3S-(1Z,3α,5β)]-[2-[3,5-bis[(1,1-dimethylethyl)dimethylsilyl)oxy]-2-methylenecyclohexylidene]ethyl]diphenylphosphine oxide in 4.0 mL of anhydrous THF was added 0.35 mL (0.56 mmol) of a 1.6 M solution of n-butyllithium in hexanes and the resultant deep red solution was stirred at −78° C. for 7 minutes. A solution of 105 mg (0.28 mmol) of [1R-(1α,3aβ,7aα)]-octahydro-7a-methyl-1-[1-[5-methyl-5-[(trimethylsilyl)oxy]pentyl]cyclopropyl]-4H-inden-4-one (Ro 27-5156) in 1.5 mL of anhydrous THF was added and the mixture was stirred at −78° C. for 3 hours and then at room temperature for 15 minutes. To the mixture was added 5 mL of a 1:1 mixture of 1.0 M Rochelle salt solution and 1.0 N KHCO3 solution. After 15 minutes the mixture was poured into 50 mL of ethyl acetate and 40 mL of a 1:1 mixture of 1.0 M Rochelle salt solution and 1.0 N KHCO3 solution. The organic phase was separated and the aqueous phase was re-extracted with 3×50 mL of ethyl acetate. The combined organic extracts were dried (Na2SO4) and evaporated to give 440 mg of a gum, which was chromatographed on 40 g of silica gel (40-65 μm mesh; 3.5 cm diameter column) with 5% ethyl acetate in hexanes as eluent, taking 12-mL fractions. Fractions 5-8 were combined and evaporated to give 131 mg of a colorless gum. The latter was dissolved in 3.0 mL of THF, treated with 1.5 mL (1.5 mmol) of a 1.0 M solution of tetra-n-butylammonium fluoride in THF, and stirred at room temperature for 17 hours. The mixture was diluted with 10 mL of water, stirred for 15 minutes, and poured into a mixture of 60 mL of ethyl acetate and 40 mL of 10% brine. The organic phase was separated and the aqueous phase was re-extracted with 3×60 mL of ethyl acetate. The combined organic extracts were washed with 4×100 mL of water, dried (Na2SO4), and evaporated to give 78 mg of a colorless gum, which was purified by flash chromatography on 40 g of silica gel (40-65 μm mesh; 3.2 cm diameter column) with ethyl acetate as eluent, taking 10-mL fractions. Fractions 10-12 were combined and evaporated to give a gum, which was dissolved in 10 mL of anhydrous methyl formate. The solution was filtered through a 0.4 μm filter and the filtrate was evaporated to give 64 mg of the title compound as a colorless foam: [α]D 25+18.3° (MeOH, c=0.18); IR (CHCl3) 3608 cm−1; 1H NMR (CDCl3) δ 0.00 (2H, m), 0.20 (2H, m), 0.59 (3H, s), 0.63 (2H, m), 0.90 (2H, m), 1.22 (6H, s), 1.30-1.70 (20H, m), 1.90-2.12 (5H, n), 2.60 (1H, d), 2.81 (1H, d), 4.22 (1H, br s), 4.43 (1H, br s), 4.99 (1H, s), 5.32 (1H, s), 5.99 (1H, d, J=11 Hz) 6.37 (1H, d, J=11 Hz); MS (EI) Calcd. for C28H44O3: m/Z 428.3290. Found n/z 428.3297.
- The compounds of the present invention are more effective than 1,25-dihydroxy vitamin D3 at bone accretion and do not induce hypercalciuria, nephrotoxicity, or hypercalcemia at therapeutically effective doses. This has been demonstrated as follows:
- Three month old rats are ovariectomized (Ovx) and administered either 1,25-dihydroxy vitamin D3 (vit. D in Table) or one of the compounds of the present invention once a day by mouth starting at 3 weeks post-ovariectomy and continuing until final sacrifice at 6 weeks post-ovariectomy. Control groups, both sham (rats that were not ovariectomized) and Ovx, received vehicle only. Blood and urine samples were collected twice, at 4 weeks post-ovariectomy and again at the 6 week mark and the amount of serum and urine calcium was determined. The final femoral calcium was determined upon sacrifice 6 weeks post-ovariectomy.
- The bone mineral density of the right femur was determined by using a High Resolution Software Package on a QDR-1000W Bone Densitometer™ (Hologic, Walthan, Mass.). The animals were scanned by placing them on a scanning block in a supine position such that the right leg was perpendicular to the main body and the tibia was perpendicular to the femur. The increase in the bone mineral density and the amount of calcium in the urine and the serum for some of the compounds of this invention in this assay are given in the table below:
Urine Whole Serum Calcium/ CPD # Femur Calcium Creatinine see Dose BMD mg/dl mg/dl Table I Surgery Treatment μg/kg/day mg/cm2 (6th Week) (6th Week) 3 Sham Vehicle 0.000 0.2457 9.17 0.29 Ovx Vehicle 0.000 0.2330 9.45 0.23 Ovx Vit D 0.200 0.2368 10.65 1.71 Ovx Cpd #3 0.010 0.2396 10.25 0.83 4 Sham Vehicle 0.000 0.2435 8.26 0.26 Ovx Vehicle 0.000 0.2228 8.57 0.31 Ovx Vit D 0.200 0.2349 9.49 1.37 Ovx Cpd #4 0.005 0.2413 8.94 0.60 - MCF-7 cells are human mammary carcinoma cells that are positive for estrogen receptors. The potential activity of vitamin D3 analogs against breast cancer was assessed from inhibition of proliferation of MCF-7 cells in culture.
- MCF-7 cells were plated at 9000 cells/well in 24-well plates and incubated at 37° C. in 5% CO2/95% air in Dulbecco's Modified Eagle Medium containing 10% fetal bovine serum, 700 nM insulin, 2 mM glutamine, 0.1 mM MEM non-essential amino acids and 1 mM sodium pyruvate. Stock solutions of vitamin D3 analogs were prepared at a concentration of 10 mM in absolute ethanol and stored at −20° C. under argon. Four days after plating, the number of MCF-7 were counted by removing the medium in 8 wells, rinsing the cells with 0.5 ml PBS without Ca/Mg and then incubating the cells with 0.3 ml of trypsin-EDTA. After 15 min., the trypsinization was stopped by adding 0.3 ml of medium. 0.2 ml aliquot was transferred from each well into dilu-vials containing 10 ml isoton and the number of cells were counted on Coulter Counter™ (Coulter, Miami, Fla.).
- MCF-7 cells in the remaining wells were refed with either control medium or medium containing varying concentrations of the vitamin D3 analog. After a further 7 days of culture, the number of MCF-7 cells in each well was assessed by removing the medium, rinsing the cells with 0.5 ml PBS without Ca/Mg and then incubating the cells with 0.5 ml of trypsin-EDTA for 15 min. The trypsinization was stopped by adding 0.5 ml of medium and 0.1 ml aliquot from each well was transferred into dilu-vials containing 10 ml isoton and the number of cells were counted on Coulter Counter™.
- The anti-cell proliferation activities (expressed as IC50, the concentration causing 50% reduction in MCF-7 cell growth in culture) of some compounds of the invention and 1,25-dihydroxy-cholecalciferol as a comparator, were:
CPD # see Table 1 IC50 (nm) 1,25-di(OH)-cholecalciferol 149 1 0.50 2 0.30 3 0.03 4 0.05 5 0.03 6 0.03 - The results of the above test show that compounds of this invention are more potent than 1,25-dihydroxy-cholecalciferol in inhibition of MCF-7 breast cells growth in culture.
- ZR-75 cells are human mammary carcinoma cells that are positive for estrogen receptors. The potential activity of vitamin D3 analogs against breast cancer was assessed from inhibition of proliferation of ZR-75 cells in culture.
- ZR-75 cells were plated at 12,500 cells/well in 24-well plates and incubated at 37° C. in 5% CO2/95% air in RPMI medium containing 10% fetal bovine serum and 2 mM L-glutamine. Stock solutions of vitamin D3 analogs were prepared at a concentration of 10 mM in absolute ethanol and stored at −20° C. under argon. One day after plating, ZR-75 cells were refed with either control medium or medium containing varying concentrations of the vitamin D3 analog. After a further 10 days of culture, the number of ZR-75 cells in each well was assessed from the reduction of the dye MTT (3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide), as described by F. Denizot and R. Lang, J. Immunological Methods, Vol. 89:271-277 (1986). MTT was added to each well to a final concentration of 1 mg/ml and the cells were incubated for a period of three hours, after which reduced MTT was extracted using 95% ethanol and the optical density was measured at a wavelength of 570 nm.
- For each vitamin D3 analog, the IC50 value was determined from a graph relating the optical density of 570 nm to the concentration used.
- The anti-cell proliferation activities (expressed as IC50, the concentration of the vitamin D3 analog corresponding to half-maximal reduction in 570 nm absorbance) of some compounds of the invention and 1,25-dihydroxy-cholecalciferol as a comparator, were:
CPD # see Table 1 IC50 (nm) 1,25-di(OH)-cholecalciferol 13 2 0.90 3 0.01 4 0.15 5 0.10 6 0.10 - The results of the above test show that compounds of this invention are more potent than 1,25-dihydroxy-cholecalciferol in inhibition of ZR-75 breast cells growth in culture.
- The parathyroid hormone suppressive activity of the vitamin D3 analogs of this invention was demonstrated in rats with secondary hyperparathyroidism due to renal failure using the 7/8 nephrectomy induced rat model of renal failure (Kidney International, M. Fukugawa et al., 39:874-881 (1991).
- Test Materials:
- Compound of Formula (I)
- 1,25 (OH)2 vitamin D3 (control)
- Vehicle—Miglyol 812
- Female Sprague Dawley rats were anesthetized, their right kidney removed and 2-3 branches of the left renal artery were ligated to achieve 7/8 nephrectomy. They were placed on a high phosphorous diet (0.6% Ca and 0.8 phosphorous). Approximately 3-6 weeks after surgery, rats were bled to screen serum PTH levels and rats with PTH levels between 100-500 pg/ml were selected for the study.
- There was a pre-bleed (T=0) and each group was dosed daily for seven days by oral lavage with either the compound of Formula (I) (0.1 μg/kg/day), vehicle control or 1, 25-(OH)2 vitamin D3 positive control. Compounds were predissolved in ethanol and diluted with vehicle (Miglyol 812) followed by evaporation of the ethanol.
- After the last day of dosing, the animals were bled again (T=1) and sacrificed. Serum PTH assays were done with Nichols Institute Diagnostic Kit #40-2240. Serum calcium assays were done with Sigma Diagnostic Kit #587 with o-cresophthalein. Serum creatinine assays were done with Sigma Diagnostic Kit #1600-320 with ammonium molybdate.
CPD # PTH pg/ml Final Ca Levels see Table 1 T = 1 − T = 0 (mg/ml) Vehicle 145 9.04 1,25(OH)2 vit. D3 (0.1 μg/kg) −18 9.75 3 (0.1 μg/kg) −70 10.65 4 (0.1 μg/kg) −137 10.08 - The results show that the compounds of Formula (I) are more effective than 1,25 (OH)2 vit. D3 in suppressing the elevated levels of parathyroid hormone.
- A capsule for oral administration is formulated under nitrogen in amber light from 0.01 to 25.0 mg of one of the compounds of the present invention in 150 mg of fractionated coconut oil, with 0.015 mg butylated hydroxytoluene (BHT) and 0.015 mg butylated hydroxyanisole (BHA), filled in a soft gelatin capsule.
- The foregoing invention has been described in some detail by way of illustration and example, for the purposes of clarity and understanding. It will be obvious to one of ordinary skill in the art that changes and modifications may be practiced within the scope of the appended claims. Therefore, it is to be understood that the above description is intended to be illustrative and not restrictive. The scope of the invention should, therefore, be determined not with reference to the above description, but should instead be determined with reference to the following appended claims, along with the full scope of equivalents to which such claims are entitled.
- The patents, patent applications and publications cited in this application are hereby incorporated by reference in their entirety for all purposes to the same extent as if each individual patent, patent application or publication were so individually denoted.
Claims (30)
1. A compound selected from the group of compounds represented by Formula (I)
wherein
X is hydrogen or ═CH2;
R1 and R2 are, independently of each other, a (C1-C4)alkyl or (C1-C4)fluoroalkyl, or R1 and R2 together with C20 form a (C3-C6)cycloalkyl or (C3-C6)cyclofluoroalkyl, or R1 and R2 together form ═CH2;
R3 and R4 are, independently of each other, a (C1-C4)alkyl or (C1-C4)fluoroalkyl, or R3 and R4 together with C25 form a (C3-C9)cycloalkyl or (C3-C9)cyclofluoroalkyl;
A is a single or a double bond; and
B is a single, double or triple bond;
and prodrugs thereof, provided that:
(i) when R1 and R2 are (C1-C4)alkyl or R1 and R2 together with C20 form a cyclopropyl group or ═CH2, R3 and R4 are (C1-C4)alkyl, trifluoromethyl or R3 and R4 together with C25 form (C3-C6)cycloalkyl and A is a single bond, then B is not a trans double bond;
(ii) when B is a single bond, then R1 and R2 together with C20 form a (C3-C6)cycloalkyl or (C3-C6)cyclofluoroalkyl group; and
(iii) when R1 and R2 are (C1-C4)alkyl, R3 and R4 are (C1-C4)alkyl, X═CH2 and A is a single bond, then B is not a double bond.
2. The compound of claim 1 , wherein:
B is a triple bond.
3. The compound of claim 2 , wherein:
R1 and R2 together with C20 form a (C3-C6)cycloalkyl;
R3 and R4 are, independently of each other, a (C1-C4)alkyl or a (C1-C4)fluoroalkyl;
X is ═CH2; and
A is a single bond.
4. The compound of claim 3 , wherein:
R1 and R2 together with C20 form a cyclopropyl group; and
R3 and R4 are, independently of each other, methyl, ethyl, trifluoromethyl, 1,1-difluoroethyl or 2,2,2-trifluoroethyl.
5. The compound of claim 4 , wherein R3 and R4 are methyl namely, 1,25-dihydroxy-23-yne-20,21,28-cyclopropyl-cholecalciferol.
6. The compound of claim 4 , wherein R3 and R4 are trifluoromethyl, namely 1,25-dihydroxy-23-yne-26,27-hexafluoro-20,21,28-cyclopropyl-cholecalciferol.
7. The compound of claim 2 , wherein:
R1 and R2 together with C20 form a (C3-C6)cycloalkyl;
R3 and R4 are, independently of each other, a (C1-C4)alkyl or a (C1-C4)fluoroalkyl;
X is hydrogen; and
A is a single bond.
8. The compound of claim 7 , wherein:
R1 and R2 together with C20 form a cyclopropyl group; and
R3 and R4 are, independently of each other, methyl, ethyl, trifluoromethyl, 1,1-difluoroethyl or 2,2,2-trifluoroethyl.
9. The compound of claim 8 , wherein R3 and R4 are methyl, namely 1,25-dihydroxy-23-yne-20,21,28-cyclopropyl-19-nor-cholecalciferol.
10. The compound of claim 8 , wherein R3 and R4 are trifluoromethyl, namely 1,25-dihydroxy-23-yne-26,27-hexafluoro-20,21,28-cyclopropyl-19-nor-cholecalciferol.
11. The compound of claim 2 , wherein:
R1 and R2 together with C20 form a (C3-C6)cycloalkyl;
R3 and R4 are, independently of each other, a (C1-C4)alkyl or a (C1-C4)fluoroalkyl;
X is ═CH2; and
A is a double bond.
12. The compound of claim 11 , wherein:
R1 and R2 together with C20 form a cyclopropyl group; and
R3 and R44 are, independently of each other, methyl, ethyl, trifluoromethyl, 1,1-difluoroethyl or 2,2,2-trifluoroethyl.
13. The compound of claim 2 , wherein:
R1 and R2 together with C20 form a (C3-C6)cycloalkyl;
R3 and R4 are, independently of each other, a (C1-C4)alkyl or a (C1-C4)fluoroalkyl;
X is H2; and
A is a double bond.
14. The compound of claim 13 , wherein:
R1 and R2 together with C20 form a cyclopropyl group; and
R3 and R4 are, independently of each other, methyl, ethyl, trifluoromethyl, 1,1-difluoroethyl or 2,2,2-trifluoroethyl.
15. The compound of claim 1 , wherein:
A is a double bond; and
B is a double bond.
16. The compound of claim 15 , wherein:
R1 and R2 together with C20 form a (C3-C6)cycloalkyl;
R3 and R4 are, independently of each other, a (C1-C4)alkyl or a (C1-C4)fluoroalkyl; and
X is ═CH2.
17. The compound of claim 16 , wherein:
R1 and R2 together with C20 form a cyclopropyl group; and
R3 and R4 are, independently of each other, methyl, ethyl, trifluoromethyl, 1,1-difluoroethyl or 2,2,2-trifluoroethyl.
18. The compound of claim 15 , wherein:
R1 and R2 together with C20 form a (C3-C6)cycloalkyl;
R3 and R4 are, independently of each other, a (C1-C4)alkyl or a (C1-C4)fluoroalkyl; and
X is H2.
19. The compound of claim 18 , wherein:
R1 and R2 together with C20 form a cyclopropyl group; and
R3 and R4 are, independently of each other, methyl, ethyl, trifluoromethyl, 1,1-difluoroethyl or 2,2,2-trifluoroethyl.
20. The compound of claim 1 , wherein:
A is a single bond; and
B is a cis double bond.
21. The compound of claim 20 , wherein:
R1 and R2 together with C20 form a (C3-C6)cycloalkyl;
R3 and R4 are, independently of each other, a (C1-C4)alkyl or a (C1-C4)fluoroalkyl; and
X is ═CH2.
22. The compound of claim 21 , wherein:
R1 and R2 together with C20 form a cyclopropyl group; and
R3 and R4 are, independently of each other, methyl, ethyl, trifluoromethyl, 1,1-difluoroethyl or 2,2,2-trifluoroethyl.
23. The compound of claim 22 , wherein R3 and R4 are trifluoromethyl namely, 1,25-dihydroxy-23-(Z)-ene-26,27-hexafluoro-20,21,28-cyclopropyl-cholecalciferol.
24. The compound of claim 20 , wherein:
R1 and R2 together with C20 form a (C3-C6)cycloalkyl;
R3 and R4 are, independently of each other, a (C1-C4)alkyl or a (C1-C4)fluoroalkyl; and
X is H2.
25. The compound of claim 24 , wherein:
R1 and R2 together with C20 form a cyclopropyl group; and
R3 and R4 are, independently of each other, methyl, ethyl, trifluoromethyl, 1,1-difluoroethyl or 2,2,2-trifluoroethyl.
26. The compound of claim 25 , wherein R3 and R4 are trifluoromethyl namely, 1,25-dihydroxy-23-(Z)-ene-26,27-hexafluoro-20,21,28-cyclopropyl-19-nor-cholecalciferol.
27. A method of treating osteoporosis via administration of a therapeutically effective amount of a compound of Formula (I)
wherein:
X is hydrogen or ═CH2;
R1 and R2 are, independently of each other, a (C1-C4)alkyl or (C1-C4)fluoroalkyl, or R and R2 together with C20 form a (C3-C6)cycloalkyl or (C3-C6)cyclofluoroalkyl, or R1 and R2 together form ═CH2;
R3 and R4 are, independently of each other, a (C1-C4)alkyl or (C1-C4)fluoroalkyl, or R3 and R4 together with C25 form a (C3-C9)cycloalkyl or (C3-C9)cyclofluoroalkyl;
A is a single or a double bond; and
B is a single, double or triple bond;
and prodrugs thereof.
28. A method of treating cancer via administration of a therapeutically effective amount of a compound of Formula (I)
wherein:
X is hydrogen or ═CH2;
R1 and R2 are, independently of each other, a (C1-C4)alkyl or (C1-C4)fluoroalkyl, or R and R2 together with C20 form a (C3-C6)cycloalkyl or (C3-C6)cyclofluoroalkyl, or R1 and R2 together form ═CH2;
R3 and R4 are, independently of each other, a (C1-C4)alkyl or (C1-C4)fluoroalkyl, or R3 and R4 together with C25 form a (C3-C9)cycloalkyl or (C3-C9)cyclofluoroalkyl;
A is a single or a double bond; and
B is a single, double or triple bond;
and prodrugs thereof, provided that:
(i) when R1 and R2 are (C1-C4)alkyl or R1 and R2 together with C20 form a cyclopropyl group or ═CH2, R3 and R4 are (C1-C4)alkyl, trifluoromethyl or R3 and R4 together with C25 form (C3-C6)cycloalkyl and A is a single bond, then B is not a trans double bond;
(ii) when B is a single bond, then R1 and R2 together with C20 form a (C3-C6)cycloalkyl or (C3-C6)cyclofluoroalkyl group; and
(iii) when R1 and R2 are (C1-C4)alkyl, R3 and R4 are (C1-C4)alkyl, X═CH2 and A is a single bond, then B is not a double bond.
29. A method of treating secondary hyperparathyroidism via administration of a therapeutically effective amount of a compound of Formula (I)
wherein:
X is hydrogen or ═CH2;
R1 and R2 are, independently of each other, a (C1-C4)alkyl or (C1-C4)fluoroalkyl, or R1 and R2 together with C20 form a (C3-C6)cycloalkyl or (C3-C6)cyclofluoroalkyl, or R1 and R2 together form ═CH2;
R3 and R4 are, independently of each other, a (C1-C4)alkyl or (C1-C4)fluoroalkyl, or R3 and R4 together with C25, form a (C3-C9)cycloalkyl or (C3-C9)cyclofluoroalkyl;
A is a single or a double bond; and
B is a single, double or triple bond;
and prodrugs thereof.
30. A pharmaceutical composition comprising an effective amount of a compound of claim 1.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/206,430 US20030083319A1 (en) | 1997-09-08 | 2002-07-25 | 1,3-Dihydroxy-20,20-dialkyl-vitamin D3 analogs |
US10/781,120 US20040167105A1 (en) | 1997-09-08 | 2004-02-18 | 1,3-dihydroxy-20,20-dialkyl-vitamin D3 analogs |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5813297P | 1997-09-08 | 1997-09-08 | |
US09/148,018 US6492353B1 (en) | 1997-09-08 | 1998-09-03 | 1,3-dihydroxy-20,20-cycloalkyl-vitamin D3analogs |
US10/206,430 US20030083319A1 (en) | 1997-09-08 | 2002-07-25 | 1,3-Dihydroxy-20,20-dialkyl-vitamin D3 analogs |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/148,018 Continuation US6492353B1 (en) | 1997-09-08 | 1998-09-03 | 1,3-dihydroxy-20,20-cycloalkyl-vitamin D3analogs |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/781,120 Continuation US20040167105A1 (en) | 1997-09-08 | 2004-02-18 | 1,3-dihydroxy-20,20-dialkyl-vitamin D3 analogs |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030083319A1 true US20030083319A1 (en) | 2003-05-01 |
Family
ID=22014900
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/148,018 Expired - Fee Related US6492353B1 (en) | 1997-09-08 | 1998-09-03 | 1,3-dihydroxy-20,20-cycloalkyl-vitamin D3analogs |
US10/206,430 Abandoned US20030083319A1 (en) | 1997-09-08 | 2002-07-25 | 1,3-Dihydroxy-20,20-dialkyl-vitamin D3 analogs |
US10/781,120 Abandoned US20040167105A1 (en) | 1997-09-08 | 2004-02-18 | 1,3-dihydroxy-20,20-dialkyl-vitamin D3 analogs |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/148,018 Expired - Fee Related US6492353B1 (en) | 1997-09-08 | 1998-09-03 | 1,3-dihydroxy-20,20-cycloalkyl-vitamin D3analogs |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/781,120 Abandoned US20040167105A1 (en) | 1997-09-08 | 2004-02-18 | 1,3-dihydroxy-20,20-dialkyl-vitamin D3 analogs |
Country Status (9)
Country | Link |
---|---|
US (3) | US6492353B1 (en) |
EP (1) | EP1015423B1 (en) |
JP (1) | JP4219553B2 (en) |
AT (1) | ATE238986T1 (en) |
AU (1) | AU1022999A (en) |
CA (1) | CA2303248A1 (en) |
DE (1) | DE69814109T2 (en) |
ES (1) | ES2196614T3 (en) |
WO (1) | WO1999012894A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050107350A1 (en) * | 2003-08-22 | 2005-05-19 | Pharmacia Corporation | Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith |
WO2006051106A1 (en) | 2004-11-12 | 2006-05-18 | Bioxell Spa | Combined use of vitamin d derivatives and anti-proliferative agents for treating bladder cancer |
WO2012047674A3 (en) * | 2010-09-27 | 2012-05-24 | Microdose Therapeutx, Inc. | Methods and compositions for disease treatment using inhalation |
US8748488B2 (en) | 2008-05-30 | 2014-06-10 | Microdose Therapeutx, Inc. | Methods and compositions for administration of oxybutynin |
US9119777B2 (en) | 2008-05-30 | 2015-09-01 | Microdose Therapeutx, Inc. | Methods and compositions for administration of oxybutynin |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19916419B4 (en) * | 1999-04-08 | 2005-06-16 | Schering Ag | Combination preparation of vitamin D metabolites or vitamin D analogues and an estrogen partial agonist for the treatment of osteoporosis |
NZ521923A (en) * | 2000-03-27 | 2004-11-26 | Wisconsin Alumni Res Found | Vitamin D compounds used to stabilize kidney transplants |
CA2735478C (en) * | 2001-01-26 | 2014-07-08 | Chugai Seiyaku Kabushiki Kaisha | Malonyl-coa decarboxylase inhibitors useful as metabolic modulators |
ATE410172T1 (en) * | 2001-05-22 | 2008-10-15 | Bioxell Spa | USE OF AN ANALOG OF VITAMIN D3 FOR THE TREATMENT OF AUTOIMMUNE DIABETES |
RU2296121C2 (en) * | 2001-09-21 | 2007-03-27 | Ф.Хоффманн-Ля Рош Аг | Compounds, method for their preparing, methods of treatment |
JP2007506765A (en) * | 2003-09-24 | 2007-03-22 | ビオクセル エッセ ピ ア | 1,3-diacylated 26,27-alkyl / haloalkylvitamin D3 compounds and methods of use thereof |
EP1797033A4 (en) * | 2004-09-24 | 2010-04-28 | Bioxell Spa | 20-cycloalkyl,26,27-alkyl/haloalkyl vitamin d3 compounds and methods of use thereof |
JP4961562B2 (en) * | 2005-03-04 | 2012-06-27 | 国立大学法人 東京医科歯科大学 | 19-norvitamin D derivative |
WO2007039322A1 (en) * | 2005-09-19 | 2007-04-12 | Bioxell Spa | Use of vitamin d3 compounds for the treatment of uveitis |
WO2012118154A1 (en) * | 2011-03-02 | 2012-09-07 | 学校法人日本大学 | Novel vitamin d receptor modulator with partial agonist activity |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5087619A (en) * | 1988-01-20 | 1992-02-11 | Hoffman-La Roche Inc. | Vitamin D3 analogs |
US4804502A (en) * | 1988-01-20 | 1989-02-14 | Hoffmann-La Roche Inc. | Vitamin D compounds |
JP2711161B2 (en) * | 1988-04-21 | 1998-02-10 | レオ・ファーマシューティカル・プロダクツ・リミテッド・エイ/エス(レーベンス・ケミスケ・ファブリック・プロデュクチオンスアクチーセルスカブ) | Novel vitamin D analog |
US4851401A (en) * | 1988-07-14 | 1989-07-25 | Wisconsin Alumni Research Foundation | Novel cyclopentano-vitamin D analogs |
US5401731A (en) * | 1989-06-29 | 1995-03-28 | Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Productionsaktieselskab) | Vitamin D analogues |
GB9017890D0 (en) * | 1990-08-15 | 1990-09-26 | Leo Pharm Prod Ltd | Chemical compounds i |
ATE143007T1 (en) | 1991-07-05 | 1996-10-15 | Duphar Int Res | VITAMIN-D DERIVATIVE, METHOD FOR THE PRODUCTION THEREOF AND INTERMEDIATE PRODUCTS THEREOF |
DE4141746A1 (en) * | 1991-12-13 | 1993-06-17 | Schering Ag | 20-METHYL-SUBSTITUTED VITAMIN D DERIVATIVES |
DK0580968T3 (en) * | 1992-05-20 | 1996-10-14 | Hoffmann La Roche | Fluorinated analogs of vitamin D3 |
DE4220757A1 (en) * | 1992-06-24 | 1994-01-05 | Schering Ag | Derivatives in the vitamin D series with modifications in the 20-position, process for their preparation, intermediates for this process, pharmaceutical preparations containing these derivatives and their use in the manufacture of medicaments |
IL107185A (en) | 1992-10-06 | 1998-02-22 | Schering Ag | Vitamin d, 25-carboxylic acid derivatives and pharmaceutical compositions containing the same |
CA2096105A1 (en) * | 1992-10-07 | 1994-04-08 | Enrico Giuseppe Baggiolini (Deceased) | Vitamin d3 fluorinated analogs |
ATE251133T1 (en) * | 1993-07-09 | 2003-10-15 | Theramex | NEW STRUCTURAL VITAMIN D DERIVATIVES |
US5552392A (en) * | 1993-11-03 | 1996-09-03 | Wisconsin Alumni Research Foundation | Method of treating hypoparathyroidism with (20S) vitamin D compounds |
US5428029A (en) * | 1993-11-24 | 1995-06-27 | Hoffmann-La Roche Inc. | Vitamin D3 fluorinated analogs |
DE59604498D1 (en) * | 1995-06-14 | 2000-03-30 | Schering Ag | VITAMIN D-DERIVATIVES WITH SUBSTITUENTS ON C-25, PROCESS FOR THEIR PRODUCTION, INTERMEDIATE PRODUCTS AND THE USE FOR THE PRODUCTION OF MEDICINAL PRODUCTS |
NO971934L (en) * | 1996-05-23 | 1997-11-24 | Hoffmann La Roche | Fluorinated vitamin D3 analogues |
AU743514B2 (en) * | 1997-05-16 | 2002-01-24 | Women & Infants Hospital | Cyclic ether vitamin D3 compounds, 1alpha (OH) 3-EPI-vitamin D3 compounds and uses thereof |
-
1998
- 1998-09-02 CA CA002303248A patent/CA2303248A1/en not_active Abandoned
- 1998-09-02 WO PCT/EP1998/005571 patent/WO1999012894A1/en active IP Right Grant
- 1998-09-02 AT AT98952587T patent/ATE238986T1/en not_active IP Right Cessation
- 1998-09-02 EP EP98952587A patent/EP1015423B1/en not_active Expired - Lifetime
- 1998-09-02 ES ES98952587T patent/ES2196614T3/en not_active Expired - Lifetime
- 1998-09-02 AU AU10229/99A patent/AU1022999A/en not_active Abandoned
- 1998-09-02 JP JP2000510706A patent/JP4219553B2/en not_active Expired - Fee Related
- 1998-09-02 DE DE69814109T patent/DE69814109T2/en not_active Expired - Lifetime
- 1998-09-03 US US09/148,018 patent/US6492353B1/en not_active Expired - Fee Related
-
2002
- 2002-07-25 US US10/206,430 patent/US20030083319A1/en not_active Abandoned
-
2004
- 2004-02-18 US US10/781,120 patent/US20040167105A1/en not_active Abandoned
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050107350A1 (en) * | 2003-08-22 | 2005-05-19 | Pharmacia Corporation | Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith |
WO2006051106A1 (en) | 2004-11-12 | 2006-05-18 | Bioxell Spa | Combined use of vitamin d derivatives and anti-proliferative agents for treating bladder cancer |
US8748488B2 (en) | 2008-05-30 | 2014-06-10 | Microdose Therapeutx, Inc. | Methods and compositions for administration of oxybutynin |
US9119777B2 (en) | 2008-05-30 | 2015-09-01 | Microdose Therapeutx, Inc. | Methods and compositions for administration of oxybutynin |
WO2012047674A3 (en) * | 2010-09-27 | 2012-05-24 | Microdose Therapeutx, Inc. | Methods and compositions for disease treatment using inhalation |
Also Published As
Publication number | Publication date |
---|---|
WO1999012894A1 (en) | 1999-03-18 |
EP1015423B1 (en) | 2003-05-02 |
EP1015423A1 (en) | 2000-07-05 |
DE69814109D1 (en) | 2003-06-05 |
US6492353B1 (en) | 2002-12-10 |
CA2303248A1 (en) | 1999-03-18 |
ATE238986T1 (en) | 2003-05-15 |
DE69814109T2 (en) | 2004-02-26 |
ES2196614T3 (en) | 2003-12-16 |
US20040167105A1 (en) | 2004-08-26 |
AU1022999A (en) | 1999-03-29 |
JP2001515881A (en) | 2001-09-25 |
JP4219553B2 (en) | 2009-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3786712B2 (en) | 2-alkyl-19-nor-vitamin D compounds | |
US6492353B1 (en) | 1,3-dihydroxy-20,20-cycloalkyl-vitamin D3analogs | |
US5872113A (en) | Fluorinated vitamin D3 analogs | |
WO1998041500A9 (en) | 2-alkyl-19-nor-vitamin d compounds | |
US6030962A (en) | Vitamin D3 analogs with bis C-20 side chains | |
EP0980354B1 (en) | Vitamin d3 analogs with bis c-20 side chains | |
US6008209A (en) | Method of using vitamin D3 analogs with bis C-20 side chains | |
AU733970B2 (en) | Fluorinated vitamin D3 analogs | |
US6559138B1 (en) | 3-Desoxy-vitamin D3 analog esters | |
AU2002338672B2 (en) | 3-desoxy-vitamin D3 analog esters | |
AU2002338672A1 (en) | 3-desoxy-vitamin D3 analog esters | |
US7491711B2 (en) | Methods of treatment using 3-desoxy vitamin D3 analogs | |
Manchand et al. | Method of using Vitamin D3 analogs with BIS C-20 side chains | |
Manchand et al. | Vitamin D3 analogs with BIS C-20 side chains | |
US5696103A (en) | Method for treating osteoporosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: HOFFMANN-LA ROCHE INC., NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MANCHAND, PERCY S.;USKOKOVIC, MILAN R.;REEL/FRAME:013149/0776 Effective date: 19981103 Owner name: SYNTEX (U.S.A.) INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MANCHAND, PERCY S.;USKOKOVIC, MILAN R.;REEL/FRAME:013149/0776 Effective date: 19981103 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |